Contact

Our Work

  • Reset Filters

  • Topic Areas

  • Content Types

  • Authors / Speakers

  • Date Range

  • Reset Filters

1281 Results

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval

Kesselheim AS, Eddings W, Raj T, Campbell EG, Franklin JM, Ross KM, Fulchino LA, Avorn J, Gagne JJ - PLOS ONE

  • Research Publications
| October 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A national survey of 718 physicians found that a strong majority (91-92%) expressed confidence in the FDA’s generic drug approval process and bioequivalence testing standards, though a minority (13-26%) remained uncomfortable prescribing certain generic drugs approved through product-specific pathways. The authors conclude that enhanced physician education about FDA generic drug approval processes and standards could help address remaining concerns and promote the use of cost-effective generic medications.
View Source

Translational Research and the U.S. Federal Elections

Kimmelman J, Kesselheim AS - Science Translational Medicine

  • Commentary & Opinion
| October 2016
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
The authors outline key translational research policy questions that presidential and congressional candidates should address, spanning basic research funding, preclinical reproducibility, clinical trial design, drug pricing, and the alignment of pharmaceutical innovation with public health priorities.
View Source

Prescription Trends—Brand-Name Drugs vs Generic (Reply)

Kesselheim AS, Gagne JJ - JAMA Internal Medicine

  • Commentary & Opinion
| October 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors respond to commentary on their survey of physician generic drug skepticism by noting that brand-name manufacturers spend $30–60 billion annually on marketing that undermines faith in generics while generic manufacturers generally cannot afford counter-marketing. They call for policy reforms to prevent drug coupons and copay assistance programs from steering patients toward expensive brand-name drugs when lower-cost generic therapeutic alternatives are available, and support institutional restrictions on pharmaceutical detailing as a means of shifting prescribing toward generics.
View Source

Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions (Reply)

Yeh JS, Franklin JM, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| October 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this exchange, critics question the authors’ study linking industry payments to brand-name statin prescribing, while the authors defend their methodology and reiterate that the association between payments and non-evidence-based prescribing patterns raises policy concerns.
View Source

Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015

Deak D, Outterson K, Powers JH, Kesselheim AS - Annals of Internal Medicine

  • Research Publications
| September 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Between January 2010 and December 2015, the FDA approved eight new antibiotics with a median clinical trial duration of 6.2 years and 666 enrolled patients per pivotal trial; seven were approved based on noninferiority rather than superiority, and seven are substantially more expensive than their comparators despite lacking demonstrated clinical superiority. The findings suggest that recent antibiotic approvals have not consistently addressed the need for demonstrably more effective treatments for multidrug-resistant infections, raising questions about whether current approval pathways adequately balance innovation incentives with evidence of meaningful clinical benefit.
View Source

Generic Drug Approvals Since the 1984 Hatch-Waxman Act

Gupta R, Kesselheim AS, Downing NS, Greene JA, Ross JS - JAMA Internal Medicine

  • Research Publications
| September 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
An analysis of all novel tablet and capsule drugs approved by the FDA from 1984 to 2016 found that among those eligible for generic competition, a significant proportion lacked adequate generic alternatives, with the number of generic approvals associated with brand-name drug characteristics including therapeutic area, orphan status, and market size. The findings provide a comprehensive picture of the generic drug landscape since the Hatch-Waxman Act, supporting the observation that limited competition for some drugs—particularly those for smaller markets—contributes to the persistence of high prices.
View Source

Effect of Generic Competition on Atorvastatin Prescribing and Patients’ Out-Of-Pocket Spending

Luo J, Seeger JD, Donneyong MM, Gagne JJ, Avorn J, Kesselheim AS - JAMA Internal Medicine

  • Research Publications
| September 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Limited initial generic competition for atorvastatin resulted in only an 18.1% reduction in brand-name prescriptions during the first 180 days after market exclusivity ended, while out-of-pocket spending remained similar between brand-name and generic formulations. Full generic competition subsequently reduced brand-name fills by 47.6% and decreased generic out-of-pocket costs to $5.10 monthly compared to $30.00 for brand-name. The findings suggest that patent exclusivity periods and delayed generic competition can substantially slow the adoption of lower-cost alternatives and delay patient savings on medication costs.
View Source

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform

Kesselheim AS, Avorn J, Sarpatwari A - JAMA

  • Research Publications
| August 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
US per capita prescription drug spending ($858 in 2013) far exceeds that of other industrialized nations (average $400), driven primarily by brand-name drug prices set based on what the market will bear rather than research and development costs, with government-granted monopoly rights and constrained payer negotiating power as the key enabling factors. The authors recommend short-term strategies including stricter exclusivity requirements, ensuring timely generic availability, expanding governmental price negotiation, generating comparative cost-effectiveness evidence, and better educating stakeholders to address rising drug costs.
View Source

The FDA, Juno Therapeutics, and the Ethical Imperative of Transparency

Hey SP, Kesselheim AS - BMJ

  • Commentary & Opinion
| August 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors argue that when serious safety events occur in clinical trials—as with three patient deaths in Juno Therapeutics’ CAR-T cell therapy trial—the details of FDA clinical holds should be publicly disclosed rather than treated as protected trade secrets, because companies have financial incentives to downplay problems with their investigational drugs.
View Source

The Emergence of the Randomized, Controlled Trial

Bothwell LE, Podolsky SH - New England Journal of Medicine

  • Commentary & Opinion
| August 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
This historical perspective traces the development of the randomized controlled trial from ancient comparative experiments through its formalization in the mid-20th century, arguing that the 1948 MRC streptomycin trial was part of a much longer evolution rather than a singular breakthrough. The authors show how intellectual, social, and regulatory forces shaped both the adoption of and resistance to controlled trials as a medical research standard.
View Source

Temporal Trends and Factors Associated with Cardiovascular Drug Development, 1990 to 2012

Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS - JACC: Basic to Translational Science

  • Research Publications
| August 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Between 1990 and 2012, the number of new cardiovascular drugs entering clinical trials declined significantly across all development stages, though the probability of successful progression was comparable to noncardiovascular drugs, with small and medium-sized companies increasingly sponsoring trials and novel drugs entering Phase 3 development. The findings highlight challenges in cardiovascular drug development, particularly the high discontinuation rates due to inadequate efficacy (44%) and safety concerns (24%), along with poor publication of Phase 3 trial results for discontinued drugs, underscoring the need for improved translational research practices and publication standards.
View Source

Switch-Backs Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence: Generics Approved By Product-Specific Approaches

Gagne JJ, Polinski JM, Jiang W, Dutcher SK, Xie J, Lii J, Fulchino LA, Kesselheim AS - Pharmacoepidemiology and Drug Safety

  • Research Publications
| August 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Switch-back rates from generic to brand-name versions for four drugs approved via product-specific FDA pathways ranged from 5 to 37 per 100 person-years, with mixed results when compared to control drugs. The findings suggest that patients using these product-specific generic drugs do not systematically return to brand-name versions at elevated rates, supporting the adequacy of product-specific approval pathways for ensuring therapeutic equivalence.
View Source

Ethical and Practical Considerations in Removing Black Box Warnings From Drug Labels

Yeh JS, Sarpatwari A, Kesselheim AS - Drug Safety

  • Commentary & Opinion
| August 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The FDA should apply a higher standard for removing boxed warnings than for imposing them, because removal may lead physicians and patients to underestimate risks. The authors call for a uniform and transparent process governing these decisions.
View Source

Balancing Benefits and Harms: Privacy Protection Policies

Sarpatwari A, Gagne JJ - Pharmacoepidemiology and Drug Safety

  • Commentary & Opinion
| August 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors highlight the tension between patient privacy protections under HIPAA and the need for data sharing to conduct post-approval drug safety research, discussing how privacy frameworks can be balanced with the public health benefits of pharmacoepidemiological studies.
View Source

Countering Imprecision in Precision Medicine

Hey SP, Kesselheim AS - Science

  • Research Publications
| July 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Despite substantial promise, precision medicine has been plagued by three inherent scientific obstacles: pivotal trials cannot be agnostic about underlying biological theories, interventions are complex “biomarker ensembles” with multiple components and degrees of uncertainty, and no single stakeholder controls the biomarkers or coordinates the research program. The authors argue that meaningful progress requires new mechanisms of scientific oversight, given that many commercially available biomarker diagnostics have not been adequately validated and even seemingly successful precision medicines like trastuzumab have been characterized by uncertainty about diagnostic test interpretation.
View Source

Why ‘Government Patent Use’ to Lower Drug Costs Won’t Stifle Innovation

Kapczynski A, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| July 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Under 28 U.S.C. Section 1498, the federal government can produce or import generic versions of patented drugs for government programs while providing patent holders “reasonable and entire compensation” keyed to R&D investment, risk of failure, and reasonable profits. Contrary to industry objections, this approach would preserve innovation incentives because companies would still receive risk-adjusted returns on investment, while generating substantial societal benefits by improving access to drugs like the hepatitis C treatment sofosbuvir (Sovaldi).
View Source

Four Ways to Address the Ethical Tensions Around Expedited Approval of New Prescription Drugs

Kesselheim AS, Hey SP, Deak D, Lo B - Health Affairs Forefront

  • Commentary & Opinion
| July 2016
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
FDA expedited approval pathways create ethical tensions between patient autonomy and adequate evidence, as drugs approved on surrogate endpoints with limited safety data may not ultimately prove effective, while patients and physicians often overestimate the rigor behind designations like “breakthrough therapy.” To address these tensions, the authors recommend strengthening post-market surveillance and confirmatory trial requirements, building consensus on definitions of unmet medical need, improving informed decision-making tools, and expanding pre-approval expanded access programs.
View Source

Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad

Luo J, Kesselheim AS - AMA Journal of Ethics

  • Research Publications
| July 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The TPP Agreement would strengthen intellectual property protections for prescription drugs through extended patent and test data exclusivity provisions, which could affect reimbursement decisions by national health authorities across signatory countries. The authors conclude that these provisions may reduce access to medicines for low-income patients in TPP signatory nations.
View Source

Federal Circuit Review of USPTO Inter Partes Review Decisions by the Numbers

Wallach EJ, Darrow JJ - Journal of the Patent and Trademark Office Society

  • Research Publications
| July 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors analyze how the America Invents Act’s inter partes review (IPR) process to provide a faster, less costly mechanism for challenging patent validity has impacted the Federal Circuit’s caseload and decision-making patterns since its implementation. By examining Federal Circuit review of USPTO IPR decisions, the study characterizes how this significant patent reform has functioned in practice and its implications for the broader patent system, including the pharmaceutical sector where patent challenges are central to generic drug competition.
View Source

Using Antitrust Law to Challenge Turing’s Daraprim Price Increase

Carrier MA, Levidow NL, Kesselheim AS - Berkeley Technology Law Journal

  • Research Publications
| June 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Turing Pharmaceuticals’ restriction of pyrimethamine distribution to a single source, combined with its resulting monopoly power, enabled a 5000% price increase and constitutes unlawful monopolization under antitrust law. The author contends that Turing’s exclusionary distribution scheme, lacking legitimate business justification and designed to block generic competition, meets the legal standard for an antitrust violation.
View Source

Navigating the Dermatological Drug Cost Curve

Sarpatwari A, Kesselheim AS - JAMA

  • Commentary & Opinion
| June 2016
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors highlight dramatic price increases for dermatologic drugs, with brand-name prices increasing a mean of 401% between 2009 and 2015, and discuss the implications for patient access and the need for policy interventions.
View Source

Comparison of Rates of Safety Issues and Reporting of Trial Outcomes for Medical Devices Approved in the European Union and United States: Cohort Study

Hwang TJ, Sokolov E, Franklin JM, Kesselheim AS - BMJ

  • Research Publications
| June 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Medical devices approved first in the European Union showed a 2.9-fold increased hazard ratio for post-marketing safety alerts and recalls compared to devices approved first in the United States, with 27% of EU-first devices experiencing safety issues versus 14% of US-first devices. Furthermore, only 49% of devices considered major innovations had their pivotal trial results published within five years of approval, demonstrating the need for greater transparency and mandatory trial publication to enable patients and clinicians to make fully informed treatment decisions.
View Source

State Initiatives to Control Medication Costs—Can Transparency Legislation Help?

Sarpatwari A, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| June 2016
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
State-level drug pricing transparency legislation, requiring manufacturers to disclose R&D costs and justify price increases, may provide valuable insight into pricing decisions, but are unlikely to meaningfully address the drivers of prescription drug spending.
View Source

Assessing the Gold Standard—Lessons from the History of RCTs

Bothwell LE, Green JA, Podolsky SH, Jones DS - New England Journal of Medicine

  • Research Publications
| June 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A historical analysis of randomized controlled trials over the past 70 years reveals that while RCTs became the gold standard for evaluating medical interventions, their development and application have been shaped by economic and political forces as much as by scientific considerations. The authors draw lessons from this history about the limitations of RCTs, including the challenges they face in addressing the complexity of medicine and disease, and the ways in which pharmaceutical industry interests have influenced their design and interpretation.
View Source

Variations in Patients’ Perceptions and Use of Generic Drugs: Results of a National Survey

Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG - Journal of General Internal Medicine

  • Research Publications
| June 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 753 surveyed patients with chronic conditions, the vast majority (80-88%) perceived generic drugs as safe, effective, and equivalent to brand-name drugs, though non-White respondents were significantly more likely to request brand-name drugs and express skepticism about generic clinical equivalence. The authors conclude that while patient attitudes toward generics have improved substantially, persistent negative perception, particularly among non-White populations, must be addressed to maximize cost savings and health outcomes associated with generic drug use.
View Source

Use the Bayh-Dole Act to Lower Drug Prices for Government Healthcare Programs

Engelberg AB, Kesselheim AS - Nature Medicine

  • Commentary & Opinion
| June 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The government should exercise its existing royalty-free license under Section 202 of the Bayh-Dole Act to authorize generic manufacturing of federally funded drugs for government healthcare programs, using enzalutamide (Xtandi) as a case study.
View Source

Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey

Kesselheim AS, Gagne JJ, Eddings W, Franklin JM, Ross KM, Fulchino LA, Campbell EG - JAMA Internal Medicine

  • Research Publications
| June 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 718 surveyed physicians, generic drugs were widely supported; 89% perceived them as effective and 91% as safe as brand-name counterpart, but 32% qualified as “generic skeptics,” and 22% last learned about generic drug availability from pharmaceutical representatives, a source significantly associated with skepticism. These findings suggest that while physicians’ views of generics have improved since earlier surveys, pharmaceutical industry marketing remains an important predictor of generic drug skepticism that could undermine cost-effective prescribing.
View Source

How Patent Troll Legislation Can Increase Timely Access to Generic Drugs

Treasure CL, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| June 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Congressional patent reform legislation targeting “patent trolls” could benefit generic drug entry by strengthening mechanisms to challenge improperly granted pharmaceutical patents and discouraging anticompetitive patent litigation settlements.
View Source

Association of Industry Payments to Physicians with the Prescribing of Brand-Name Statins in Massachusetts

Yeh JS, Franklin JM, Avorn J, Landon JE, Kesselheim AS - JAMA Internal Medicine

  • Research Publications
| June 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among Massachusetts physicians prescribing statins under Medicare in 2011, those receiving industry payments prescribed brand-name statins at significantly higher rates than those receiving no payments, with each $1,000 in total payments associated with a 0.1% increase in brand-name prescribing and educational training payments showing a particularly strong association with a 4.8% increase in brand-name prescribing. These findings raise concerns about the cost implications of industry payments to physicians and suggest that efforts to reduce prescription drug costs should consider addressing financial relationships between pharmaceutical companies and prescribing physicians.
View Source

Anti-VEGF Therapy in Ophthalmology: A Qualitative Analysis of Transformative Drug Development

Caplan ES, Kesselheim AS - Drug Discovery Today

  • Research Publications
| June 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Anti-VEGF inhibitors have revolutionized treatment of vasoproliferative eye diseases through decades of extensive basic science research and multidisciplinary academic collaboration, particularly among Harvard-affiliated scientists and clinicians who developed a deep understanding of VEGF mechanisms. The development of these transformative drugs demonstrates that robust basic science and academic collaboration are critical drivers of breakthrough drug development, while competitive market forces subsequently drive private investment.
View Source

Op-Ed: A Simple Way for the Government to Curb Inflated Drug Prices

Rizvi Z, Kapczynski A, Kesselheim AS - Washington Post

  • Commentary & Opinion
| May 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Drawing an analogy between overpriced patented drugs and strategic holdouts in eminent domain, the authors argue the federal government should use its existing “government patent use” authority to negotiate lower prices or purchase generic versions of essential medications for government programs. They cite the precedent of the 2001 anthrax crisis and argue that applying this approach to drugs like the hepatitis C treatment Sovaldi could dramatically expand patient access while still providing manufacturers reasonable compensation for their investment.
View Source

Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea

Kim SC, Choi N, Lee J, Kwon K, Eddings W, Sung Y, Ji Song H, Kesselheim AS, Solomon DH - Arthritis & Rheumatology

  • Research Publications
| May 2016
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Following the introduction of biosimilar infliximab in South Korea in November 2012, biosimilar infliximab claims reached 19% of all infliximab claims by March 2014. The introduction also altered overall TNF inhibitor use patterns, with increases in combined infliximab usage and decline in etanercept and adalimumab prescriptions. The findings demosntrate how biosimilars can alter market dynamics within therapeutic classes, though results may differ in other countries.
View Source

The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?

Rathi VK, Kesselheim AS, Ross JS - JAMA Cardiology

  • Commentary & Opinion
| May 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors analyze the FDA’s 515 Program Initiative—designed to reclassify high-risk medical devices that had been cleared through the less rigorous 510(k) pathway—using the Impella percutaneous ventricular assist device as a case study of how the FDA can promote rigorous assessment of widely used but inadequately evaluated devices.
View Source

Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections

Hwang TJ, Kesselheim AS - American Journal of Law & Medicine

  • Research Publications
| May 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This empirical analysis of FDA-approved clinical trials over the past decade finds that antibiotic trials are not larger or more difficult to conduct than trials for other drugs targeting high unmet medical needs, contradicting assumptions that trial size is a primary barrier to antibiotic development. The authors recommend that policymakers focus on alternative regulatory levers beyond trial size reduction and evaluate how new and existing approval pathways can be designed to prioritize and expedite therapeutics with the greatest potential to benefit patients with serious drug-resistant infections.
View Source

‘Government Patent Use’: A Legal Approach to Reducing Drug Spending

Kapczynski A, Kesselheim AS - Health Affairs

  • Research Publications
| May 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors propose that the federal government invoke its existing “government patent use” authority to procure generic versions of patented drugs, such as direct-acting antivirals for hepatitis C, while paying patent holders reasonable royalties, thereby reducing drug costs that currently create treatment barriers and enable monopoly pricing. This approach would allow federal programs to treat more patients with clinically appropriate medicines at lower costs while still compensating companies for research and development investments.
View Source

Efficacy of the Priority Review Voucher Program (Reply)

Sarpatwari A, Kesselheim AS - JAMA

  • Commentary & Opinion
| April 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors argue that the priority review voucher program is not a sensible way to incentivize tropical disease drug development because it disrupts the FDA’s calibrated review process, risks wasting public funds by accelerating reimbursement of potentially noninnovative drugs by government insurance programs, and is easily gamed. Instead, greater NIH funding should be directed toward translational tropical disease research.
View Source

Physicians’ Knowledge About FDA Approval Standards and Perceptions of the “Breakthrough Therapy” Designation

Kesselheim AS, Woloshin S, Eddings W, Franklin JM, Ross KM, Schwartz LM - JAMA

  • Research Publications
| April 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A survey of 675 board-certified internists and specialists found widespread misunderstanding of FDA approval standards. 73% incorrectly believed approval means a drug is as effective as others for the same condition, and only 6% correctly identified that FDA approval requires neither a statistically significant nor a clinically important result specifically. When presented with 2 identical hypothetical drugs differing only in whether one carried the “breakthrough” label, physicians significantly preferred prescribing the designated “breakthrough” drug, demonstrating that the term influences prescribing behavior independent of actual clinical evidence.
View Source

Testimony on the Impact of S.1048: A Bill to Improve Transparency of Drug Research and Development Costs

Kesselheim AS - Massachusetts General Court, Joint Committee on Health Care Financing

  • Policy Interactions
| April 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
An icon of a bill representing government policy.
View Source

Breakthrough Medical Devices and the 21st Century Cures Act

Kesselheim AS, Hwang TJ - Annals of Internal Medicine

  • Commentary & Opinion
| April 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The proposed “breakthrough device” designation in the 21st Century Cures Act should learn from the experience of the breakthrough therapy program for drugs, where the designation’s name can mislead consumers and some designated products subsequently failed in clinical trials.
View Source

Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine

Capati VC, Kesselheim AS - Journal of Managed Care & Specialty Pharmacy

  • Research Publications
| April 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Forest Laboratories’ introduction of an extended-release memantine formulation while restricting access to the previous version exemplifies product hopping, a strategy that can disrupt stable patient treatment regimens and increase costs while potentially forestalling generic competition. Policy solutions to limit anticompetitive product hops include raising patentability standards for new drug formulations and reforming automatic generic substitution laws to preserve patient access to existing treatments.
View Source

Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis

Wang B, Franklin JM, Eddings W, Landon JE, Kesselheim AS - PLOS ONE

  • Research Publications
| March 2016
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This retrospective time-series analysis of antipsychotic prescriptions from 2003 to 2012 found that FDA action on pediatric supplemental new drug applications for olanzapine, quetiapine, and ziprasidone did not significantly alter prescribing patterns in children compared to adults, with no differential impact between approvals and rejections. The authors conclude that FDA determinations regarding pediatric antipsychotic use are not effectively translating into clinical practice and recommend improved communication strategies to convey the agency’s regulatory decisions to prescribers.
View Source

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion

Hey SP, Kesselheim AS - PLOS Medicine

  • Research Publications
| March 2016
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors challenge the federal court ruling that sided with Amarin Pharmaceutical’s First Amendment claim to promote its fish oil product Vascepa for an unapproved indication, arguing that the company’s so-called “truthful and non-misleading” statement was actually a tautology—logically true by construction but not consistent with the state of scientific evidence and therefore misleading to prescribers. They propose that informativeness in asserting scientific facts, rather than mere truthfulness, should be the standard for evaluating commercial speech about pharmaceuticals.
View Source

The First Amendment and Pharmaceutical Promotion

Avorn J - Health Affairs Forefront

  • Commentary & Opinion
| March 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The growing movement to treat pharmaceutical promotional claims as constitutionally protected commercial free speech threatens FDA’s ability to regulate drug marketing, despite the fact that neither patients nor physicians can independently evaluate the voluminous proprietary data underlying drug approvals. History demonstrates the dangers of loosened regulation: from over $15 billion in industry settlements for illegal off-label promotion to the current flood of unsubstantiated claims for dietary supplements exempted from FDA oversight.
View Source

Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?

Wang B, Kesselheim AS - JAMA

  • Commentary & Opinion
| March 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors examine the regulatory classification challenges for drug-device combination products, arguing that how these products are classified (as primarily a drug or device) has important implications for the evidence required before marketing and for patient safety.
View Source

Inaccurate Reporting of Insulin Reimbursement (Reply)

Luo J, Avorn J, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| March 2016
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
In this exchange, critics argue that the authors’ analysis of Medicaid insulin reimbursement incorrectly assumed fixed rebate rates, while the authors address the methodological challenge of estimating net prices in a system where actual rebate amounts are confidential.
View Source

Addressing Generic Drug Unaffordability and Shortages By Globalizing the Market for Old Drugs

Engelberg AB, Avorn J, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| February 2016
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Consolidation among generic manufacturers, FDA approval backlogs, and predatory pricing strategies have created natural monopolies for many older generic drugs, leading to severe shortages and price spikes like Turing’s 5,000% increase for pyrimethamine (Daraprim). The FDA should accept quality assurance determinations from comparable foreign regulatory agencies and grant expedited review for drugs with three or fewer US manufacturers, creating a global market that restores competition without requiring new legislation.
View Source

Expanding Coercive Treatment Is the Wrong Solution for the Opioid Crisis

Beletsky L, Parmet WE, Sarpatwari A - Health Affairs Forefront

  • Commentary & Opinion
| February 2016
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Massachusetts’s proposed STEP Act would allow clinicians and police to impose 72-hour involuntary holds on individuals with substance use disorders without judicial oversight, but evidence suggests forced treatment leads to higher relapse rates and could deter people from seeking help. Rather than expanding coercive measures that strain already overburdened treatment facilities and undermine civil liberties, policymakers should invest in evidence-based alternatives such as expanded treatment capacity, prescription monitoring, and emergency department case management.
View Source

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire Upon Generic Entry?

Sarpatwari A, Kesselheim AS - PLOS Medicine

  • Commentary & Opinion
| February 2016
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
Allowing generic drugs to share the brand names of their originator counterparts after market exclusivity ends could help reduce wasteful spending on brand-name products, since persistent brand-name recognition contributes to slower generic uptake.
View Source

Vaccine Pipeline Has Grown During the Past Two Decades with More Early-Stage Trials From Small and Medium-Size Companies

Hwang TJ, Kesselheim AS - Health Affairs

  • Research Publications
| February 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Over the past two decades, the proportion of new vaccine candidates entering clinical development increased by 3-5%, with small and medium-size companies initiating nearly twice as many Phase I trials as large companies, though late-stage trials remained dominated by large firms. The authors recommend policy interventions such as prizes and public-private partnerships targeted at smaller companies to support vaccine development for unmet medical needs and emerging public health threats.
View Source

Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method

Yeh JS, Van Hoof TJ, Fischer MA - American Health & Drug Benefits

  • Research Publications
| February 2016
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Using a three-round Delphi method with 20 academic detailing experts, researchers achieved 92% consensus agreement on key features of academic detailing, including focused clinician education, tailored messaging with feasible strategies, and specific skill sets for detailers to overcome barriers to behavior change. The consensus-derived template of general principles can serve as a useful standard for implementing and evaluating academic detailing initiatives.
View Source

Insulin Patents and Market Exclusivities: Unresolved Issues (Reply)

Luo J, Kesselheim AS - Lancet Diabetes & Endocrinology

  • Commentary & Opinion
| February 2016
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
Responding to commentary on the global implications of U.S. insulin patent landscapes, the authors outline two regulatory pathways for follow-on insulin approval—the 505(b)(2) pathway and the Biologics Price Competition and Innovation Act—and warn that after 2020, regulatory transitions could create a problematic gap in which no follow-on insulin application could be approved. They argue that the key factor for affordability will be whether follow-on insulins achieve interchangeability status, and caution that biosimilar insulins alone, without additional policy interventions, are unlikely to produce meaningful near-term cost reductions for patients.
View Source

Testimony in Support of H.866: an Act Relating to Prescription Drug Manufacturer Cost Transparency

Sarpatwari A, Fischer MA - Vermont General Assembly, House Committee on Health Care

  • Policy Interactions
| January 2016
  • Price, Value, and Access
An icon of a bill representing government policy.
View Source

Regulating Homeopathic Products—A Century of Dilute Interest

Podolsky SH, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| January 2016
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors trace the regulatory history of homeopathic products in the US, noting that these products have largely escaped the evidence-based scrutiny required of conventional drugs since the 1938 Food, Drug, and Cosmetic Act, and discuss recent FDA and FTC efforts to reconsider this regulatory gap.
View Source

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib

Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey SP, London AJ, Kimmelman J - Journal of the National Cancer Institute

  • Research Publications
| January 2016
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Across 103 clinical trials of sunitinib (Sutent) monotherapy, the drug achieved an objective response rate of 15.7% while 1.08% of patients died from drug-related toxicities and 13.7% experienced grade 3-4 adverse events, with the risk/benefit ratio worsening as the development program progressed. The authors recommend that research decision-making should evaluate evidence from entire drug development programs rather than isolated studies to better identify when continued testing in new indications is unlikely to be beneficial.
View Source

Two Decades of New Drug Development for Central Nervous System Disorders

Kesselheim AS, Hwang TJ, Franklin JM - Nature Reviews Drug Discovery

  • Research Publications
| December 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
An analysis of 379 CNS drugs entering clinical trials between 1990 and 2012 revealed a substantial decline in the relative proportion of CNS drug Phase I trial starts compared to oncology drugs, and CNS drugs were 45% less likely than non-CNS drugs to progress from Phase III to regulatory filing with inadequate efficacy accounting for 46% of Phase III discontinuations. These findings support the need for greater investment in CNS basic research and biomarker validation rather than relaxed approval standards, given that high Phase III failure rates suggest many CNS drugs are advancing on the basis of marginal Phase II results.
View Source

The 21st Century Cures Act: Opportunities and Challenges

Sarpatwari A, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Commentary & Opinion
| December 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors discuss the 21st Century Cures Act, analyzing how its provisions for expedited drug development and use of novel evidence could affect the balance between patient access and safety.
View Source

Regulatory Solutions to the Problem of High Generic Drug Costs

Luo J, Sarpatwari A, Kesselheim AS - Open Forum Infectious Diseases

  • Commentary & Opinion
| December 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors examine dramatic price increases for select generic drugs (such as pyrimethamine’s 5,000% markup) that occur when companies acquire monopolies in markets with limited competition, and propose regulatory solutions including expedited FDA review for competitive generics, importation from regulated markets, and antitrust enforcement.
View Source

Physicians and Insider Trading

Kesselheim AS, Sinha MS, Joffe S - JAMA Internal Medicine

  • Research Publications
| December 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Recent high-profile cases demonstrate that physicians and scientists with access to confidential information about clinical trials or corporate governance have engaged in insider trading, which undermines the legitimate benefits of their involvement in business decision-making. Minimizing insider trading requires robust education, strictly enforced contracts, and selective prohibitions on high-risk activities such as expert consulting networks for individuals with access to valuable inside information.
View Source

Medical Schools’ Industry Interaction Policies Not Associated with Trainees’ Self-Reported Behavior as Residents: Results of a National Survey

Yeh JS, Austad KE, Franklin JM, Chimonas S, Campbell EG, Avorn J, Kesselheim AS - Journal of Graduate Medical Education

  • Research Publications
| December 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Residents who graduated from medical schools with restrictive industry interaction policies were no more or less likely than those from schools with permissive policies to accept industry gifts, attend sponsored lectures, or prefer brand-name medications, though residents with stronger evidence-based prescription knowledge were less likely to attend industry-sponsored lectures. The findings suggest that medical school policies’ protective effects against pharmaceutical marketing do not persist into residency, indicating that residency training environments play a critical role in shaping prescribing and industry interactions.
View Source

Do March‐in Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study

Treasure CL, Avorn J, Kesselheim AS - Milbank Quarterly

  • Research Publications
| December 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Since the Bayh-Dole Act’s enactment in 1980, the NIH has received only 5 march-in rights petitions for 4 federally-funded health products and rejected all of them, with qualitative analysis of expert interviews revealing little prospect that the agency will invoke march-in rights to address high drug prices or ensure public access. Although march-in rights may encourage government licensees to commercialize research results and extract minor concessions from licensees, the current statutory language makes these rights unlikely to serve as an effective policy tool for lowering prices of medical products derived from federal funding.
View Source

Cost-Effectiveness of Statin Therapy for ASCVD

Luo J, Kesselheim AS - JAMA

  • Research Publications
| November 2015
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
In response to a microsimulation study finding statin therapy cost-effective for over 60% of US adults aged 40-75, the authors highlight that real-world drug costs may substantially exceed the wholesale acquisition costs used in the modl and that widespread lack of transparency in drug pricing, including legislatively restricted disclosure of average manufacturer prices and Medicaid rebates, complicates interpretation of cost-effectiveness analyses that rely on prescription medication costs.
View Source

Reductions in Use of Colchicine After FDA Enforcement of Market Exclusivity in a Commercially Insured Population

Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH - Journal of General Internal Medicine

  • Research Publications
| November 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Following FDA enforcement of market exclusivity for brand-name colchicine (Colcrys), colchicine initiation rates decreased significantly among both gout patients and FMF patients, while average monthly prescription drug costs increased from $418 to $651 and total health care costs rose from $3,406 to $3,534. The FDA’s enforcement action reduced colchicine use and increased patient spending without achieving improvements in avoiding potentially dangerous drug interactions with clarithromycin or cyclosporine.
View Source

Evolution of Insulin Patents and Market Exclusivities in the USA

Luo J, Kesselheim AS - Lancet Diabetes & Endocrinology

  • Research Publications
| November 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A comparison of patents covering US insulin products in 2004 and 2014 reveals a dramatic shift in the intellectual property landscape: while active patents on insulin more than doubled (from 8 to 19), pen-device patents grew from 0% to 53% of all patents while the proportion of patents covering the active ingredient decreased from 50% to 21%. The authors note that intellectual property barriers alone do not fully explain the lack of generic competition, as many insulin active ingredients have no remaining patent or exclusivity protection, and they call on the FDA to issue clear guidance for follow-on insulin approval to reduce market entry hurdles for potential generic competitors.
View Source

Comparative Effectiveness of Generic Versus Brand-Name Antiepileptic Medications

Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH - Epilepsy & Behavior

  • Research Publications
| November 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Patients initiating generic antiepileptic drugs (AEDs) experienced significantly fewer seizure-related hospitalizations or emergency room visits and demonstrated longer treatment persistence compared to those initiating brand-name versions of the same medications. These findings suggest that generic AEDs are at least as effective as brand-name formulations and may provide equivalent or superior clinical outcomes for Medicare beneficiaries with epilepsy.
View Source

Experience with the Priority Review Voucher Program for Drug Development

Kesselheim AS, Maggs LR, Sarpatwari A - JAMA

  • Research Publications
| October 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Through August 2015, the FDA had issued 6 priority review vouchers—3 for neglected tropical diseases and 3 for rare pediatric diseases—but several vouchers were awarded for drugs that were already approved abroad, based on previously conducted trials, or associated with safety signals, while vouchers were sold for up to $350 million each. The authors detail how the program’s design has allowed companies to earn substantial financial rewards without necessarily conducting new research, suggesting that the voucher program may not be achieving its goal of incentivizing novel drug development for neglected diseases.
View Source

The 21st Century Cures Act—Will It Take Us Back in Time? (Reply)

Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| October 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this exchange, supporters of the 21st Century Cures Act argue that it does not lower FDA standards but rather enables the use of new evidence tools like biomarkers and real-world data, while the authors reply that the bill’s provisions could authorize the FDA to rely on less rigorous data, particularly for antibiotic approvals and surrogate endpoints, potentially undermining patient safety.
View Source

The Daraprim Price Hike and A Role for Antitrust

Carrier MA, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| October 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Turing Pharmaceuticals’ 5,000% price increase for pyrimethamine (Daraprim) was facilitated by a restricted distribution system that appears designed to prevent generic competitors from obtaining the drug samples needed for FDA bioequivalence testing. This conduct presents a viable antitrust claim under existing monopolization precedents that federal agencies and private plaintiffs should pursue.
View Source

The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines

Luo J, Kesselheim AS - JAMA

  • Commentary & Opinion
| October 2015
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The stronger patent protections and data exclusivity requirements demanded by the US in the Trans-Pacific Partnership (TPP) Agreement’s pharmaceutical intellectual property provisions could restrict access to essential medicines in developing partner countries by delaying generic drug availability.
View Source

Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014

Luo J, Avorn J, Kesselheim AS - JAMA Internal Medicine

  • Research Publications
| October 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Between 1991 and 2014, Medicaid reimbursement per unit of insulin increased substantially across all insulin types, rising from $2.36-$4.43 in the 1990s to $9.64-$19.81 by 2014, with patent-protected insulins increasing at a faster rate ($0.20 per quarter) than non-patented insulins ($0.05 per quarter). These findings indicate a lack of price competition in the US insulin market and suggest the need for policy interventions to address rising insulin costs for patients and insurers.
View Source

Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-Up Studies to Ensure Safety and Effectiveness

Kesselheim AS, Gagne JJ - Drug Safety

  • Commentary & Opinion
| October 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors describe how the FDA uses product-specific testing pathways, rather than standard bioequivalence studies, to approve certain complex generic drugs. They argue that while these flexible approaches are necessary to avoid delays in generic availability, they should be followed by active post-approval surveillance to confirm safety and effectiveness.
View Source

Trends in Utilization of FDA Expedited Drug Development and Approval Programs, 1987-2014: Cohort Study

Kesselheim AS, Wang B, Franklin JM, Darrow JJ - BMJ

  • Research Publications
| September 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 774 drugs approved by the FDA from 1987 to 2014, there was a significant 2.6% annual increase in the number of expedited programs (orphan drug, fast track, accelerated approval, and priority review) granted per newly approved drug, along with a 2.4% annual increase in the proportion of drugs associated with at least one such program. This trend was driven by an increase in the use of expedited programs for non-first-in-class drugs, which are potentially less innovative, suggesting that programs originally intended for drugs providing notable clinical advances are being applied increasingly broadly.
View Source

Characteristics of Efficacy Evidence Supporting Approval of Supplemental Indications for Prescription Drugs in United States, 2005-14: Systematic Review

Wang B, Kesselheim AS - BMJ

  • Research Publications
| September 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 295 supplemental indications approved by the FDA from 2005 to 2014, only 30% of new indication approvals were supported by trials with active comparators compared to 51% of modified use approvals and 11% of population expansion approval. Clinical outcome endpoints were used in just 22-32% of trials across approval types. The findings highlight substantial variations in evidence standards for supplemental indications, particularly for pediatric population expansions.
View Source

FDA Policy and Cardiovascular Medicine

Ross JS, Kesselheim AS - Circulation

  • Research Publications
| September 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This comprehensive review traces the FDA’s evolution from its 1862 origins through landmark legislation—the 1906 Pure Food and Drug Act, 1938 Food Drug and Cosmetic Act, 1962 Kefauver-Harris Amendments, and 1976 Medical Device Amendments—each enacted in response to public health crises and broadening the agency’s authority over drugs and devices. The authors discuss current FDA policies for approval and postmarket surveillance of new drugs, biologics, generics, and medical devices, with particular attention to their implications for cardiovascular clinical care.
View Source

Op-Ed: An Age-Old Battle: The FDA Versus the Shill

Greene JA, Kesselheim AS - The Atlantic

  • Commentary & Opinion
| September 2015
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In the wake of Kim Kardashian’s paid Instagram promotion of the morning sickness drug Diclegis in 2015, the authors trace the FDA’s longstanding challenge of regulating pharmaceutical marketing across successive new media, from national magazines and radio to social media. They argue that while the regulatory landscape has evolved significantly since the 1906 Pure Food and Drugs Act, celebrity testimonials and the tension between commercial speech and consumer protection remain as relevant as ever.
View Source

Comments on Proposed Rule, “Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY2016”

Sarpatwari A, Kesselheim AS, Avorn J - Centers for Medicare and Medicaid Services (CMS)

  • Policy Interactions
| September 2015
  • Price, Value, and Access
An icon of a bill representing government policy.
CMS’s proposed blended reimbursement system for follow-on biologics would assign non-unique billing codes that prevent product-specific safety surveillance, undermining the pharmacovigilance research needed to build physician and patient confidence in this important new class of lower-cost treatments.
View Source

Brief of Harvard Law School Center for Health Law and Policy Innovation, et al. in Gobeille v. Liberty Mutual

Sarpatwari A, Kesselheim AS - US Supreme Court

  • Policy Interactions
| September 2015
  • Price, Value, and Access
An icon of a bill representing government policy.
The amici argue that ERISA should not preempt Vermont’s statute requiring self-funded insurance plans to report health care claims data to the state’s all-payer claims database (APCD), because ERISA’s reporting requirements cover only financial information while APCDs collect entirely distinct clinical and utilization data. APCDs provide uniquely comprehensive datasets essential for health services research, policy analysis, and public health surveillance that cannot be adequately studied using fragmented data from individual insurers.
View Source

Forbidden and Permitted Statements About Medications—Loosening the Rules

Avorn J, Sarpatwari A, Kesselheim AS - New England Journal of Medicine

  • Research Publications
| September 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A federal court ruling in 2015 sided with Amarin Pharmaceutical’s claim that the First Amendment protects its right to promote its fish oil product Vascepa for an unapproved indication, provided the statements are “truthful,” representing the latest in a series of legal and regulatory developments weakening FDA authority over off-label drug promotion. The authors examine how this expanding interpretation of commercial speech rights threatens the longstanding regulatory tradition of requiring manufacturers to demonstrate efficacy before making promotional claims, with potentially significant implications for patient safety and evidence-based prescribing.
View Source

Propofol as a Transformative Drug in Anesthesia: Insights From Key Early Investigators

Bateman BT, Kesselheim AS - Drug Discovery Today

  • Research Publications
| August 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Through a modified Delphi survey and in-depth qualitative interviews, experts identified propofol (Diprivan) as the most transformative drug in anesthesiology over the past 25 years, with its development driven by a positive research environment at Imperial Chemical Industries and the central role of individual academic anesthesiologists outside the company. This case study provides lessons for promoting transformative drug innovation, highlighting the importance of clinician-scientists in translating early discoveries into clinically impactful products.
View Source

The Safety of Prescription Drugs

Sharfstein JM, Kesselheim AS - JAMA

  • Commentary & Opinion
| July 2015
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors discuss the ongoing challenges of post-market drug safety surveillance, advocating for a consistent FDA decision-making framework that establishes evidence thresholds for different regulatory responses (further study, boxed warnings, market withdrawal) as recommended by the Institute of Medicine.
View Source

Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?

Kesselheim AS, Darrow JJ - Yale Journal of Health Policy, Law and Ethics

  • Research Publications
| July 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The Hatch-Waxman Act of 1984 successfully established the modern generic drug industry, which now accounts for 84 percent of all prescriptions but only 20 percent of drug costs; however, emerging challenges including deliberate system manipulation and unfavorable court decisions like PLIVA v. Mensing have created problems in the generic drug market. The authors propose updates to the Hatch-Waxman Act to address these challenges and ensure the continued timely emergence of safe generic drugs.
View Source

The 21st Century Cures Act—Will It Take Us Back in Time?

Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| June 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
While the 21st Century Cures Act includes welcome NIH funding increases, key provisions could weaken FDA approval standards by encouraging reliance on less rigorous evidence such as observational data, surrogate endpoints, and adaptive trial designs. The authors argue that the current drug approval process is already efficient and that lowering evidence thresholds risks approving drugs that are ineffective or harmful.
View Source

Progress and Hurdles for Follow-On Biologics

Sarpatwari A, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| June 2015
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
The authors assess the state of the biosimilar market following the FDA’s first biosimilar approval (filgrastim-sndz), identifying barriers to uptake including physician skepticism, insurer preauthorization requirements, and state substitution law restrictions.
View Source

Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications

Kesselheim AS, Campbell EG, Schneeweiss SG, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J - Drug Safety

  • Research Publications
| June 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors describe a multidisciplinary research framework for evaluating the effectiveness of two FDA Drug Safety Communications issued in 2013 regarding zolpidem (Ambien), incorporating drug utilization analysis, health outcomes assessment, comparison with the non-affected comparator eszopiclone (Lunesta), patient surveys, and traditional and social media dissemination analysis. This integrated approach aims to generate insights that can optimize future FDA risk communications by better understanding how safety messaging influences physician and patient decision-making across multiple channels.
View Source

Accelerating Innovation in Rapid Diagnostics and Targeted Antibacterials

Hwang TJ, Powers JH, Carpenter D, Kesselheim AS - Nature Biotechnology

  • Commentary & Opinion
| June 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Policy efforts to combat antibiotic resistance should prioritize narrow-spectrum antibiotics paired with rapid diagnostic tests. The atuhors argue that this approach could delay resistance and reduce adverse effects compared with broad-spectrum agents, and recommend a pilot regulatory pathway to facilitate their development.
View Source

Precision Medicine and the FDA’s Draft Guidance on Laboratory-Developed Tests

Hwang TJ, Lehmann LS, Kesselheim AS - Nature Biotechnology

  • Commentary & Opinion
| May 2015
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this letter to the editor, the authors discuss FDA regulatory policy around laboratory-developed tests in the context of precision medicine, addressing the regulatory framework for ensuring the safety and effectiveness of diagnostic technologies that underpin personalized treatment decisions.
View Source

To Spur Medical Innovation, Make Corporate Cheaters Pay

Kesselheim AS, Sarpatwari A - Health Affairs Forefront

  • Commentary & Opinion
| April 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The Medical Innovation Act would require pharmaceutical companies that engage in illegal marketing practices to pay additional fees based on their profits and number of federally funded blockbuster drugs, channeling those funds to the NIH and FDA. The legislation would both increase accountability for industry fraud, whose profits far exceed existing penalties, and boost funding for the basic science research and regulatory infrastructure that drive truly transformative drug development.
View Source

Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs (Reply)

Sarpatwari A, Darrow JJ, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| April 2015
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
In this exchange, FDA officials and the authors discuss the challenges and safeguards of expanded access to unapproved drugs, including the application process complexities and the balance between patient access and maintaining clinical trial integrity.
View Source

Additional Comments on Proposed Rule, “Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products”

Sarpatwari A, Kesselheim AS - Food and Drug Administration (FDA)

  • Policy Interactions
| April 2015
  • Regulation and Clinical Evidence
An icon of a bill representing government policy.
The commenters opposed an industry-backed alternative to the FDA’s proposed generic drug labeling rule, arguing that the “Expedited Agency Review” proposal would remove incentives for manufacturers to monitor their products for emerging safety issues and result in fewer and slower label updates needed to protect patients.
View Source

Variations in Time of Market Exclusivity Among Top-Selling Prescription Drugs in the United States

Wang B, Liu J, Kesselheim AS - JAMA Internal Medicine

  • Research Publications
| April 2015
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 437 top-selling US prescription drugs from 2000 to 2011, only 40% experienced generic competition by end of 2012, with substantial variation by therapeutic area. Endocrinology drugs had the lowest rate of generic availability (14%) while infectious disease drugs had the highest (63%). The findings demonstrate how market exclusivity periods are influenced by a combination of regulatory exclusivities, original and secondary patents, settlement agreements, and other commercial factors, with implications for policies aimed at promoting more timely generic competition across therapeutic classes.
View Source

Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes

Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ - Drugs

  • Research Publications
| April 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A systematic review of six drugs approved via modified bioequivalence approaches found limited post-approval evidence overall—only 26 studies met inclusion criteria, most were susceptible to bias, and notably, the brand-name manufacturers who raised scientific concerns about generic versions prior to approval did not conduct rigorous post-approval clinical testing to substantiate those concerns. Despite pre-approval controversy, the available evidence generally supported generic bioequivalence and clinical interchangeability, though the authors call for more systematic post-approval study of generic drugs subject to modified bioequivalence determinations.
View Source

A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?

Darrow JJ, Kesselheim AS - Food and Drug Law Journal

  • Research Publications
| April 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A growing class of non-communicable disease (NCD) vaccines is being developed to target conditions such as cancer, hypertension, addiction, and obesity by modulating the immune system against disease-associated cells or molecules rather than pathogens, but these products differ fundamentally from traditional vaccines in their risk-benefit profile, target populations, and lack of herd immunity benefits. The authors argue that these differences raise important regulatory questions for the FDA about whether NCD vaccines should be evaluated under the same framework as infectious disease vaccines or as biologic drugs, and whether the term “vaccine” is even appropriate for this emerging therapeutic category.
View Source

Ensuring Timely Approval of Generic Drugs

Sarpatwari A, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| March 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Brand-name manufacturers are exploiting FDA risk evaluation and mitigation strategies (REMS) to block generic competition by refusing to provide drug samples needed for required bioequivalence testing, and in some cases patenting their REMS programs to artificially extend market exclusivity. The authors advocate for the FAST Generics Act, which would create an FDA-authorized pathway for generic manufacturers to obtain brand-name drug samples regardless of REMS status, and call on Congress to create a safe harbor protecting generic manufacturers from patent infringement claims when replicating a brand-name drug’s REMS for a bioequivalent product.
View Source

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States

Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS - PLOS Medicine

  • Research Publications
| March 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
With brand-name drug prices increasing 15% in 2014 alone while generic drugs (86% of prescriptions) have saved consumers nearly $1.5 trillion over the past decade, the authors examine strategies to promote greater generic and biosimilar prescribing, including traditional approaches like formulary decision support and academic detailing, as well as novel financial incentives for physicians. While private insurers may legally offer physicians payments for prescribing generics, the authors argue that the developing evidence base warrants caution for therapeutic substitution and narrow therapeutic index drugs, and that any physician-centered incentive programs must be accompanied by comparative cost-utility studies assessing patient outcomes.
View Source

The Watchman Saga—Closure at Last?

Kramer DB, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| March 2015
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors trace the regulatory history of the Watchman left atrial appendage closure device, which was available in Europe for nearly a decade before US approval, highlighting differences between US and EU device regulation and the importance of requiring clinical evidence for high-risk implantable devices.
View Source

Mandatory Disclaimers on Dietary Supplements Do Not Reliably Communicate the Intended Issues

Kesselheim AS, Connolly JG, Rogers JR, Avorn J - Health Affairs

  • Research Publications
| March 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
In this systemic review of dietary supplement disclaimer studies, larger and more rigorous studies revealed that many consumers were unaware of disclaimers or that they did not affect patient perceptions of supplements. These findings suggest that relying on disclaimers as an alternative to government restrictions on drug marketing would be inadequate for informing patients about drug efficacy and safety, and risk enabling a return to problematic levels of inappropriate prescription drug use.
View Source

Availability and Utilization of Cardiovascular Fixed-Dose Combination Drugs in the United States

Wang B, Choudhry NK, Gagne JJ, Landon JE, Kesselheim AS - American Heart Journal

  • Research Publications
| March 2015
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among patients treated for diabetes, dyslipidemia, and hypertension in 2012, only 15% of the 20 most frequently filled single-agent drug pairs were available as fixed-dose combinations (FDCs), and FDCs that existed had substantially lower utilization rates than the most common single-agent pairs. The authors recommend implementing expedited approval pathways and increased investment in formulation studies to better align the development of FDCs with actual clinical use patterns.
View Source

Paying for Innovation: Reimbursement Incentives for Antibiotics

Hwang TJ, Carpenter D, Kesselheim AS - Science Translational Medicine

  • Research Publications
| February 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Despite antibiotics’ tremendous social value, lower perceived commercial potential has driven several large pharmaceutical companies to abandon antibiotic research. The authors examine how reforming hospital reimbursement policies for inpatient antibiotic use could serve as a “pull” mechanism to better align financial incentives with the urgent clinical and public health need for new antibiotics targeting multidrug-resistant organisms.
View Source

High-Cost Generic Drugs—Implications for Patients and Policymakers (Reply)

Alpern JD, Stauffer WM, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| February 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
Responding to FDA officials, the authors acknowledge that faster generic drug application review is helpful but argue that additional interventions are needed to address the multiple causes of high generic drug prices, including fluctuating demand and anticompetitive business practices.
View Source

The Roles of Academia, Rare Diseases, and Repurposing in the Development of the Most Transformative Drugs

Kesselheim AS, Tan YT, Avorn J - Health Affairs

  • Research Publications
| February 2015
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This study of twenty-six transformative drugs approved by the FDA between 1984 and 2009 found that most originated from academic research supported by federal funding or joint public-private development, with only a minority developed solely within pharmaceutical industry programs. Additionally, 35% were repurposed drugs and 38% were initially developed for rare diseases. These findings suggest that policies should recognize the critical roles of academic research, drug repurposing, rare disease research, and government funding in generating transformative pharmaceutical innovations.
View Source

Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review

Kesselheim AS, Huybrechts KF, Choudhry NK, Fulchino LA, Isaman DL, Kowal MK, Brennan TA - American Journal of Public Health

  • Research Publications
| February 2015
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Broader prescription drug insurance coverage reduces utilization of other healthcare services and improves patient health outcomes, while coverage gaps or caps lead to worse outcomes, based on a systematic review of 23 empirical studies. States should implement Affordable Care Act drug coverage expansions to enhance health outcomes for low-income patients enrolled in state-based health insurance programs.
View Source

Development and Use of New Therapeutics for Rare Diseases: Views From Patients, Caregivers, and Advocates

Kesselheim AS, McGraw SA, Thompson L, O'Keefe K, Gagne JJ - The Patient

  • Research Publications
| February 2015
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Rare disease patients, caregivers, and advocates reported willingness to accept risks with novel or off-label treatments due to limited therapeutic options, while expressing frustration with high costs and insufficient scientific data about available treatments. Yet, respondents also valued the FDA’s regulatory oversight and the scientific rigor of drug development. These findings suggest that regulatory frameworks for rare disease therapeutics should balance accelerated access to treatments with maintained scientific standards, while addressing patient concerns about affordability and data transparency.
View Source

Are Risk Evaluation and Mitigation Strategies Associated with Less Off-Label Use of Medications? The Case of Immune Thrombocytopenia

Sarpatwari A, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Research Publications
| February 2015
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The study found that when Risk Evaluation and Mitigation Strategies (REMS) requirements were in place for romiplostim and eltrombopag, prescribing was almost exclusively on-label; after these requirements were removed, off-label use of eltrombopag for hepatitis C virus patients increased significantly. The findings suggest that while REMS programs can promote patient safety by limiting off-label use, they may also restrict access to potentially beneficial off-label applications.
View Source

A Cross‐National Comparison of 17 Countries’ Insulin Glargine Drug Labels

Polinski JM, Kesselheim AS, Seeger JD, Connolly JG, Choudhry NK, Shrank WH - Pharmacoepidemiology and Drug Safety

  • Research Publications
| February 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This cross-national analysis of insulin glargine drug labels across 17 countries found substantial variability in label content, with critical gaps including only 12% describing care of fasting patients, 24% lacking guidance on missed doses, and 29% failing to recommend counseling about hypoglycemia risk; additionally, labels from regional or adopted regulatory bodies reported significantly fewer patients in efficacy studies compared to labels from independent drug regulatory agencies (365 vs. 3,560 patients). The authors conclude that these inconsistencies in drug label content may compromise the quality and consistency of insulin therapy and patient care internationally.
View Source

Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs

Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Research Publications
| January 2015
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA’s expanded access system allows patients with serious conditions to receive investigational drugs before formal approval through 3 categories: individual use, intermediate-size populations, and widespread treatment protocols. The authors examine the practical, legal, and ethical challenges of reconciling protection of vulnerable, seriously ill patients from potentially useless or harmful products with the desire to provide timely access to treatments that may ultimately prove beneficial, drawing on cases like Josh Hardy’s widely publicized request for an experimental antiviral and the Ebola crisis.
View Source

Pharmaceutical Gatekeepers

Darrow JJ - Indiana Law Review

  • Research Publications
| January 2015
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Drawing on Kraakman’s influential framework on third-party gatekeepers in corporate finance, the article applies a gatekeeping analysis to the pharmaceutical marketplace, examining how diverse entities, including the FDA, USPTO, FTC, physicians, insurance companies, and patients, serve as potential gatekeepers against pharmaceutical misconduct. The analysis explores how these federal agencies and private actors, each wielding different powers to withhold support from potentially harmful pharmaceutical practices, can more effectively deter wrongdoing in a complex regulatory landscape.
View Source

Medical Device Postapproval Safety Monitoring: Where Does the United States Stand?

Rajan PV, Kramer DB, Kesselheim AS - Circulation: Cardiovascular Quality and Outcomes

  • Research Publications
| January 2015
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
As the FDA considers expedited approval pathways for high-risk medical devices to address unmet medical needs, the reduced premarket evidence places greater pressure on postapproval surveillance to identify emerging safety problems. The authors analyze the FDA’s current postmarket programs, including passive reporting through Medical Device Reporting, prospective clinical studies, and active device registries, assessing their effectiveness for monitoring cardiovascular devices and identifying prospects for strengthening the postmarket surveillance network.
View Source

FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes

Kesselheim AS, Darrow JJ - Clinical Pharmacology & Therapeutics

  • Research Publications
| January 2015
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA’s expedited development and review pathways, including the 2012 breakthrough therapy designation, allow approval of drugs with less rigorous data than standard requirements and now account for a majority of new drug approvals, offering benefits in bringing transformative drugs to market more efficiently. However, these pathways carry risks of post-approval determinations of ineffectiveness or safety problems and create confusion among patients and physicians about what FDA approval signifies.
View Source

Comments on Proposed Criteria for “First Generic” Submissions for Purposes of ANDA Review Prioritization Under GDUFA

Alpern JD, Stauffer WM, Kesselheim AS - Food and Drug Administration (FDA)

  • Policy Interactions
| December 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
An icon of a bill representing government policy.
The FDA should expand its generic drug application review prioritization criteria to include markets experiencing significant price increases due to lack of competition, in order to help counteract the growing trend of exorbitant price hikes for older, off-patent generic drugs.
View Source

Burden of Changes in Generic Pill Appearance (Reply)

Kesselheim AS, Choudhry NK, Avorn J - Annals of Internal Medicine

  • Commentary & Opinion
| December 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors counter the FDA’s concern that requiring generic drugs to resemble their brand-name counterparts would violate “trade dress” protections, arguing that Supreme Court precedent prohibits trade-dress rights for functional product features. They urge the FDA to formally acknowledge in a guidance document that bioequivalent generic drugs resembling their brand-name counterparts enhance patient safety, which would provide factual input guiding courts to find such appearance features functional and therefore unprotectable by trademark.
View Source

Innovative Research Methods for Studying Treatments for Rare Diseases: Methodological Review

Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS - BMJ

  • Research Publications
| November 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This methodological review identified 16 research strategies for studying health outcomes in rare diseases, with innovative clinical trial methods primarily focusing on minimizing sample size requirements and maximizing patient access to active treatment. While unique clinical trial designs have been developed for rare disease research, there is a significant gap in innovative observational study methods for this population, suggesting a need for greater methodological development in observational research approaches.
View Source

Testimony: Why Are Some Generic Drugs Skyrocketing in Price?

Kesselheim AS - 113th Congress, Senate Committee on Health, Education, Labor, and Pensions

  • Policy Interactions
| November 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
An icon of a bill representing government policy.
Kesselheim explains that while generic drugs reliably deliver low-cost, high-quality medications, competition among manufacturers can collapse due to business decisions, supply disruptions, anticompetitive behavior, or re-assertion of exclusivity righs. To mitigate generic drug price spikes, he recommends mandatory reporting of price increases above 100%, expedited FDA review for new generic entrants into monopolized markets, increased FTC enforcement resources, and waiving Medicare Part D’s non-interference clause for multisource drugs. Read his written testimony.
View Source

High-Cost Generic Drugs—Implications for Patients and Policymakers

Alpern JD, Stauffer WM, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| November 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors document dramatic price increases for off-patent drugs with limited competition driven by manufacturer consolidation, supply disruptions, and the discontinuation of therapeutic alternatives. To mitigate these price spikes, they propose various policy solutions, including FDA-triggered public solicitations for new generic manufacturers when substantial price increases occur, expedited reviews and user fee waivers for companies entering these markets, and temporary importation.
View Source

The Short-Term and Long-Term Outlook of Drug Coupons

Maggs LR, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| November 2014
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
While manufacturer drug coupons reduce patients’ out-of-pocket costs and may improve short-term adherence, they undermine cost-sharing mechanisms designed to steer prescribing toward equally effective, less expensive alternatives, ultimately increasing insurer spending and premiums for all patients. Policymakers face a tension between individual patient savings and systemwide costs, and coupons further dampen public pressure for broader drug pricing reform by masking the true price burden.
View Source

Chemotherapy Parity Laws: A Remedy for High Drug Costs?

Wang B, Joffe S, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| November 2014
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
While oral chemotherapy parity laws (requiring insurers to cover oral cancer drugs on terms comparable to intravenous chemotherapy) improve patient access, they are an inadequate response to the fundamental problem of rising cancer drug costs and may actually reduce pressure on manufacturers to moderate prices.
View Source

Ensuring Patient Privacy in Data Sharing for Postapproval Research

Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss SG - New England Journal of Medicine

  • Commentary & Opinion
| October 2014
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors detail the HIPAA and HITECH Act pathways for sharing health data for post-approval drug safety research, assessing the usefulness and liability risks of each pathway and arguing for frameworks that enable robust pharmacoepidemiological research while protecting patient privacy.
View Source

Association of Medical Students’ Reports of Interactions with the Pharmaceutical and Medical Device Industries and Medical School Policies and Characteristics: A Cross-Sectional Study

Yeh JS, Austad KE, Franklin JM, Chimonas S, Campbell EG, Avorn J, Kesselheim AS - PLOS Medicine

  • Research Publications
| October 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Students attending medical schools with the most stringent policies on pharmaceutical and medical device industry interactions were significantly less likely to report receiving gifts and interacting with industry representatives compared to those at schools with less restrictive policies, though this association was attenuated when accounting for NIH funding levels. Medical schools should emphasize policies that limit gifts, meals, and faculty participation in speaking bureaus, and policymakers should prioritize implementing stronger industry interaction regulations at less research-intensive institutions.
View Source

Health Policy Basics: The Physician Payment Sunshine Act and the Open Payments Program

Kirschner NM, Sulmasy LS, Kesselheim AS - Annals of Internal Medicine

  • Commentary & Opinion
| October 2014
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The Open Payments program is a US government transparency initiative that requires public reporting of financial relationships between pharmaceutical and device industries and physicians or teaching hospitals, without assessing the appropriateness of those relationships. The authors outline the program’s requirements and implementation timeline, examine implications for physicians and patients, and offer recommendations to help physicians and teaching hospitals prepare for compliance.
View Source

Existing FDA Pathways Have Potential to Ensure Early Access To, and Appropriate Use Of, Specialty Drugs

Kesselheim AS, Tan YT, Darrow JJ, Avorn J - Health Affairs

  • Research Publications
| October 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA has multiple regulatory tools to balance timely patient access to specialty drugs, which offer substantial clinical benefits but carry significant risks and high costs, including expanded access programs and expedited approval pathways to accelerate availability, as well as post-approval mechanisms like narrow indications, companion diagnostics, and Risk Evaluation and Mitigation Strategies (REMS). The authors argue that effective implementation of these existing approaches can promote access for patients most likely to benefit while preventing expensive and potentially harmful overuse.
View Source

A Matter of Trust: Patient Barriers to Primary Medication Adherence

Polinski JM, Kesselheim AS, Frolkis JP, Wescott P, Allen-Coleman C, Fischer MA - Health Education Research

  • Research Publications
| October 2014
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Focus groups with 26 patients who failed to fill initial antihypertensive prescriptions revealed key barriers to primary medication adherence, including anger and suspicion about the hypertension diagnosis, doubts about the need for medication, and concerns about provider credibility. Participants indicated that a trusting patient-provider relationship, shared decision-making, full disclosure of side effects, and cost sensitivity could improve adherence, suggesting that decision support interventions focused on building trust and credibility before prescribing may be more effective than current approaches.
View Source

Electronic Medication Packaging Devices and Medication Adherence: A Systematic Review

Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS - JAMA

  • Research Publications
| September 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Electronic medication packaging (EMP) devices show variable effectiveness in improving medication adherence, with effect estimates ranging from a 2.9% decrease to a 34.0% increase in mean adherence across 37 studies. Devices integrated into the care delivery system and designed to record dosing events demonstrated the most consistent associations with improved adherence. Higher-quality evidence is needed to definitively establish the effectiveness of EMP devices in addressing medication nonadherence and to identify which specific device components are most beneficial.
View Source

Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study

Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH - Annals of Internal Medicine

  • Research Publications
| September 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Medicare patients who initiated generic statins demonstrated higher medication adherence and had an 8% lower rate of acute coronary syndrome, stroke, or all-cause mortality compared to those initiating brand-name statins. These findings suggest that generic statins may offer clinical advantages over brand-name statins, though results may not generalize to populations with different incomes or drug benefit structures.
View Source

Regulating Incremental Innovation in Medical Devices

Kesselheim AS, Rajan PV - BMJ

  • Commentary & Opinion
| September 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The rapid evolution of medical devices through incremental design changes—with cardiac devices averaging 50 FDA applications over their regulatory lifespans—creates patient safety risks when these modifications are cleared without clinical testing. The authors call for active post-marketing surveillance linked to compulsory research.
View Source

The Role of Black Box Warnings in Safe Prescribing Practices

Maggs LR, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| August 2014
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors discuss how the FDA’s accelerated approval timelines under PDUFA have contributed to a rise in post-approval black box warnings and market withdrawals, using cases like rofecoxib (Vioxx) and the SSRI-suicidality controversy to illustrate the challenges of calibrating drug safety communications. Black box warnings must be data-driven, appropriately nuanced, and timely despite manufacturer resistance, and over-broad application risks diluting their signal value.
View Source

The Food and Drug Administration’s Role in Promoting Consistent Labels for Generic Drugs

Duke JD, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| August 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors examine an FDA proposal that would allow generic drug manufacturers to independently update their product labels with new safety information, arguing that while the rule could improve the timeliness of safety warnings, the potential for temporarily inconsistent labels across manufacturers of the same drug is a valid but manageable concern given that generic labels already frequently differ in practice.
View Source

Introduction to a Supplement on Innovative Approaches to Studying Health Outcomes in Rare Diseases

Kesselheim AS, Gagne JJ - Journal of General Internal Medicine

  • Commentary & Opinion
| August 2014
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors introduce a journal supplement highlighting the growing importance of rare diseases in health policy and the need for innovative research methods, noting that rare disease drugs are increasingly approved on weaker evidence and that novel approaches to trial design, patient registries, and outcome measurement are needed.
View Source

Improving Evidence-Based Practices Through Health Literacy

Yeh JS - JAMA Internal Medicine

  • Commentary & Opinion
| August 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
This letter to the editor discusses the importance of health literacy in enabling patients to meaningfully participate in clinical decision-making, arguing that mismatches between patient skills and the complexity of health information lead to poor communication and suboptimal care.
View Source

Association of Marketing Interactions with Medical Trainees’ Knowledge About Evidence-Based Prescribing: Results From a National Survey

Austad KE, Avorn J, Franklin JM, Campbell EG, Kesselheim AS - JAMA Internal Medicine

  • Research Publications
| August 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Medical trainees with higher acceptance of pharmaceutical industry interactions demonstrated significantly lower odds of selecting evidence-based prescribing choices and were more likely to recommend brand-name drugs over generics. The findings suggest that institutional policies limiting direct pharmaceutical sales representative interactions with medical students and residents may improve trainees’ evidence-based prescribing knowledge and reduce bias toward branded medications.
View Source

FDA Regulation of Mobile Health Technologies

Cortez NG, Cohen IG, Kesselheim AS - New England Journal of Medicine

  • Research Publications
| July 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
With over 97,000 mobile health apps available as of 2013 and the market nearly doubling annually, the FDA faces a major regulatory challenge in overseeing an increasingly diverse range of mHealth products—from smartphone-connected glucometers to cardiac monitoring apps—that blur the line between consumer wellness tools and medical devices. The authors examine how to balance the FDA’s public health mandate to ensure device safety and effectiveness with concerns from Congress and industry that excessive regulation could inhibit innovation in this rapidly growing market.
View Source

Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction: Cohort and Nested Case-Control Studies

Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK - Annals of Internal Medicine

  • Research Publications
| July 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 11,513 post-MI patients initiating generic cardiovascular medications, 29% experienced a change in pill color or shape. These changes were significantly associated with medication nonpersistence, as odds of discontinuation increased 34% after a color change and 66% after a shape change. These findings suggest that inconsistencies in generic drug appearance may meaningfully disrupt adherence to essential cardiovascular therapies and highlight the importance of pill appearance standardization or better patient communication around such changes.
View Source

Testimony: 21st Century Cures: Modernizing Clinical Trials

Kesselheim AS - 113th Congress, House Committee on Energy and Commerce, Subcommittee on Health

  • Policy Interactions
| July 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
An icon of a bill representing government policy.
Kesselheim argues that the FDA’s requirement for rigorous premarket testing of drugs and high-risk devices emerged as a rational response to public health tragedies, and that the agency already has substantial flexibility to expedite important new products. He cautions that approving drugs based on unvalidated trial designs or surrogate endpoints puts patients at risk, citing bedaquiline as a cautionary example, and notez that post-approval confirmatory studies and safety surveillance systems remain underdeveloped. Read his written testimony.
View Source

New FDA Breakthrough-Drug Category—Implications for Patients (Reply)

Darrow JJ, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| July 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this reply, the authors maintain that the FDA itself acknowledges its expedited-approval programs lower evidentiary thresholds, and that the breakthrough-therapy designation can indirectly weaken standards by generating premature enthusiasm that pressures the agency into approving drugs based on truncated trials and unvalidated biomarkers.
View Source

New Drug and Device Approval: What Is Sufficient Evidence?

Darrow JJ, Kesselheim AS - Health Affairs Forefront

  • Commentary & Opinion
| July 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Growing pressure to expedite drug and device approvals through pathways like accelerated approval creates risks of premature market entry for products later found ineffective or harmful, as illustrated by cases like the Wingspan stent where a larger trial revealed increased stroke and death rates. While expedited access is appropriate for seriously ill patients with no alternatives, the FDA must maintain robust evidentiary standards as its default position, since Type I approval errors are unusually resistant to correction once products reach the market.
View Source

Drug Development and FDA Approval, 1938-2013

Darrow JJ, Kesselheim AS - New England Journal of Medicine

  • Research Publications
| June 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This interactive graphic shows major legislative and regulatory events related to approval of new drugs by the Food and Drug Administration (FDA), drug approvals by year and by therapeutic category, and trends in the use of the FDA’s various programs for expedited approval.
View Source

Restrictions on Pharmaceutical Detailing Reduced Off-Label Prescribing of Antidepressants and Antipsychotics in Children

Larkin I, Ang D, Avorn J, Kesselheim AS - Health Affairs

  • Research Publications
| June 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Restrictions on pharmaceutical detailing at academic medical centers reduced off-label prescribing of antidepressants and antipsychotics in children by 11%, while on-label prescribing of promoted drugs fell 34% and prescriptions shifted toward nonpromoted drugs. These findings suggest that anti-detailing policies can effectively limit pharmaceutical marketing’s influence on prescribing in pediatric populations and promote evidence-based treatment practices.
View Source

Prospects for Regulation of Off-Label Promotion in an Era of Expanding Commercial Speech Protection

Kesselheim AS, Mello MM - North Carolina Law Review

  • Research Publications
| June 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The Second Circuit Court of Appeals ruled in United States v. Caronia that the criminal prosecution of a pharmaceutical sales representative for orally promoting an FDA-approved drug (Xyrem) for off-label uses violated First Amendment protections of commercial speech, overturning his misbranded drug conspiracy conviction. The decision represents a legal setback for government efforts to regulate aggressive pharmaceutical marketing and raises questions about the government’s ability to enforce FDA restrictions on off-label drug promotion under expanding commercial speech protections.
View Source

Evidence, Errors, and Ethics

Miller FG, Joffe S, Kesselheim AS - Perspectives in Biology and Medicine

  • Research Publications
| June 2014
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Evidence-based decisions relating to the development and use of novel medical interventions are liable to false positive and false negative errors: adverse consequences that ensue from making or omitting to make a given decision. The authors examine the propensity to false positive and false negative errors in light of competing value judgments in the areas of designing randomized controlled trials, pharmaceutical licensing, coverage of medical treatments, and clinical practice.
View Source

Crowdsourcing Public Health Experiments: A Response to Jonathan Darrow’s Crowdsourcing Clinical Trials

Sarpatwari A, Robertson CT, Yokum DV, Joiner K - Minnesota Law Review

  • Research Publications
| June 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Responding to Darrow’s proposal for crowdsourcing post-approval drug surveillance through observational data collection, the authors qualify the ethical framing of early clinical drug use as equivalent to research and highlight the limitations of observational approaches compared to randomized designs for drawing causal inferences. They expand on Darrow’s core insights by proposing that crowdsourcing platforms could be used not only for pharmaceutical surveillance but also for truly randomized interventional trials in lifestyle-driven domains which are primary drivers of health outcomes and spending.
View Source

Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology

Rome BN, Kramer DB, Kesselheim AS - Current Cardiology Reports

  • Research Publications
| June 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Recent high-risk medical device recalls, particularly involving ICD leads, have highlighted concerns that FDA premarket approval does not guarantee superior safety or effectiveness, as many widely used devices are approved as supplements to existing PMA-approved devices with limited clinical testing. Cardiologists should recognize the variable levels of evidence underlying FDA device approvals and prioritize clinician and patient engagement in postmarket surveillance and comparative effectiveness research to ensure optimal device safety and performance.
View Source

Target Small Firms for Antibiotic Innovation

Hwang TJ, Carpenter D, Kesselheim AS - Science

  • Research Publications
| May 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Analysis of 4,715 drugs entering Phase 1 trials between 1990 and 2012 found that antibiotics were 43% more likely than other drugs to survive Phase 2 and 17% more likely to survive Phase 3, while small and medium-sized companies grew from under 30% to 60% of antibiotic clinical trial sponsors during this period. The authors argue that policies should focus on supporting these smaller firms through targeted R&D tax credits, public-private partnerships, and increased basic research funding rather than extending market exclusivity or lowering regulatory standards.
View Source

Postmarketing Trials and Pediatric Device Approvals

Hwang TJ, Kesselheim AS, Bourgeois FT - Pediatrics

  • Research Publications
| May 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Most high-risk pediatric devices approved between 2008 and 2011 (88% of 25 devices) were based on nonrandomized, open-label studies using surrogate endpoints, with 84% never studied in patients under 18 years of age before approval. While the FDA mandated postmarketing studies for 76% of approved devices, only 18% of these studies required enrollment of pediatric patients, indicating limited postmarket surveillance in the intended pediatric population.
View Source

Using a Drug-Safety Tool to Prevent Competition

Sarpatwari A, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| April 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors document how some brand-name manufacturers have exploited FDA REMS requirements to block generic competition by refusing to provide drug samples for bioequivalence testing and hindering development of shared REMS programs.
View Source

Accelerating Medicines Partnership: A New Public-Private Collaboration for Drug Discovery

Kesselheim AS, Tan YT - Health Affairs Forefront

  • Commentary & Opinion
| April 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The Accelerating Medicines Partnership brings together the NIH, ten major pharmaceutical companies, and nonprofit groups with $230 million in initial funding to collaboratively identify and validate biological targets for Alzheimer’s disease, type 2 diabetes, rheumatoid arthritis, and lupus, with all early-stage data made publicly accessible. Key challenges include managing the transition from open collaboration to proprietary development, aligning divergent public and private incentives, and ensuring that drugs emerging from taxpayer-supported research are priced fairly rather than imposing a double burden on the public.
View Source

New FDA Breakthrough-Drug Category—Implications for Patients

Darrow JJ, Avorn J, Kesselheim AS - New England Journal of Medicine

  • Research Publications
| March 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Created by Congress in 2012, the FDA’s breakthrough therapy designation was intended to expedite approval of drugs showing “exceptional results for patients,” yet in its first year the FDA received 92 applications, far exceeding expectations of approximately 2 per year, and approved 27 designations, raising concerns about a potential surge in drugs approved on the basis of limited clinical data. The authors trace the history of prior expedited-access programs and examine the clinical, ethical, and regulatory implications of this latest pathway, noting the dangers illustrated by cases like ponatinib, which was briefly suspended after accelerated approval when serious thromboembolic events emerged in up to 48% of patients.
View Source

Comments on Proposed Rule, “Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products”

Kesselheim AS, Avorn J, Duke JD - Food and Drug Administration (FDA)

  • Policy Interactions
| March 2014
  • Regulation and Clinical Evidence
An icon of a bill representing government policy.
The commenters support an FDA proposed rule that would allow generic drug manufacturers to update their drug labels through expedited procedures, addressing a gap in safety oversight that leaves generic drug labels outdated when new safety information emerges after brand-name exclusivity ends.
View Source

Comments on Draft Guidance, “Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules”

Kesselheim AS, Avorn J, Engelberg AB - Food and Drug Administration (FDA)

  • Policy Interactions
| March 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
An icon of a bill representing government policy.
The FDA should expand its guidance on generic drug appearance to address pill color, given research showing that changes in the color and shape of generic medications contribute to patient confusion, medication non-adherence, and negative health outcomes.
View Source

What Is the Public’s Right to Access Medical Discoveries Based on Federally Funded Research?

Treasure CL, Avorn J, Kesselheim AS - JAMA

  • Commentary & Opinion
| March 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors examine the Bayh-Dole Act’s march-in rights as a mechanism to ensure public access to drugs developed with federal funding, reviewing the history of march-in petitions to the NIH and arguing that these rights should be exercised when publicly funded drugs are priced beyond patients’ reach.
View Source

Underrepresentation of Older Adults in Cancer Trials

Luo J, Kesselheim AS - JAMA

  • Commentary & Opinion
| March 2014
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
This letter to the editor discusses methodological issues in observational studies examining testosterone therapy and cardiovascular outcomes, including the use of inverse probability weighting and the importance of accounting for time-varying treatment initiation.
View Source

Strategies for Postmarketing Surveillance of Drugs for Rare Diseases

Kesselheim AS, Gagne JJ - Clinical Pharmacology & Therapeutics

  • Research Publications
| March 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Rare diseases affect 6-8% of the population and represent the fastest-growing category of new drug approvals, yet traditional postmarketing surveillance methods like meta-analyses and spontaneous adverse event reporting are inadequate for these populations due to their low prevalence and poorly characterized natural history. Bayesian trials, distributed networks of electronic databases, natural history studies, adaptive clinical trial designs, and patient-organized registries offer promising alternative methodological approaches for active and prospective monitoring of rare disease therapeutics.
View Source

Assessing the Chiral Switch: Approval and Use of Single-Enantiomer Drugs, 2001 to 2011

Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS - American Journal of Managed Care

  • Research Publications
| March 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
From 2001 to 2011, the FDA approved 9 single-enantiomer drugs as chiral switches, yet only 3 had preapproval trials directly comparing them to their racemic precursors, and none demonstrated superior efficacy at comparable doses. Meanwhile, Medicaid spent approximately $6.3 billion on these products during this period. The findings suggest that chiral switches are often approved and widely adopted without robust evidence of clinical superiority over existing racemic formulations, raising questions about the drug approval process.
View Source

Clinicians’ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation

Kesselheim AS, Xu S, Avorn J - PLOS ONE

  • Research Publications
| February 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Three teams of physician-inventors, Palmaz and Schatz, Gianturco and Roubin, and Sigwart, independently identified the clinical need for coronary artery stents and developed prototypes with support from academic medical centers before larger companies subsequently entered the field with engineering expertise. Innovation policy should prioritize supporting early-stage physician-inventors working at academic institutions, as this case study demonstrates that transformative medical device innovation originates from clinicians addressing unmet clinical needs rather than from corporate-led development.
View Source

The Evolving Role of Biomarker Patents in Personalized Medicine

Kesselheim AS, Shiu N - Clinical Pharmacology & Therapeutics

  • Commentary & Opinion
| February 2014
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
The authors analyze how recent Supreme Court decisions have narrowed the scope of biomarker patents by ruling that purely mental processes correlating biomarkers with clinical outcomes are unpatentable, while processes integrating biomarkers into practical clinical steps can still receive patent protection.
View Source

Quantifying the Food and Drug Administration’s Rulemaking Delays Highlights the Need for Transparency

Hwang TJ, Avorn J, Carpenter D, Kesselheim AS - Health Affairs

  • Research Publications
| February 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
FDA rules published between 2000 and 2012 had a median finalization time of 7.3 years, with mandatory cost-benefit analyses adding approximately two years of delay, and longer review times associated with less stringent final rules compared to proposed versions. The authors recommend increasing FDA resources to improve rulemaking efficiency and implementing transparency initiatives across the FDA and executive branch.
View Source

FDA Approval of Cardiac Implantable Electronic Devices Via Original and Supplement Premarket Approval Pathways, 1979-2012

Rome BN, Kramer DB, Kesselheim AS - JAMA

  • Research Publications
| January 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
From 1979 to 2012, the FDA approved 77 original premarket approval applications for cardiac implantable electronic devices with a median of 50 supplements per original application. 37% of supplements involved design changes, yet only 23% of the supplements approved from 2010 to 2012 included new clinical data. The findings highlight that most modifications to high-risk cardiac devices are approved without additional clinical testing, underscoring the critical need for rigorous postapproval surveillance to ensure ongoing safety and effectiveness.
View Source

Assessment of US Pathway for Approving Medical Devices for Rare Conditions

Hwang TJ, Carpenter D, Kesselheim AS - BMJ

  • Research Publications
| January 2014
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The humanitarian device exemption (HDE), established by the Safe Medical Devices Act of 1990 for devices treating diseases affecting fewer than 4,000 US patients annually, does not require manufacturers to demonstrate effectiveness, only safety and a favorable benefit-risk balance. Restrictions on for-profit sales were also removed for pediatric devices in 2007 and all HDE devices in 2012. The authors examine the scientific and regulatory characteristics of HDE-approved devices since the pathway’s inception, considering benefits and risks of this reduced evidentiary standard and drawing lessons for ongoing regulatory reform efforts in both the US and EU.
View Source

Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs

Xu S, Kesselheim AS - Journal of Law, Medicine & Ethics

  • Research Publications
| Winter 2014
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors surveyed innovators responsible for transformative drugs from the 1980s and 1990s about how the drug development process has changed and what factors drove breakthrough discoveries. The insights from these key historical figures provide an empirical basis for evaluating current proposals to stimulate medical innovation, including whether reducing regulatory approval hurdles or creating new translational research incentives are likely to address the underlying causes of the slowdown in transformative drug development.
View Source

Life Cycle of Medical Product Rules Issued By the US Food and Drug Administration

Hwang TJ, Avorn J, Kesselheim AS - Journal of Health Politics, Policy and Law

  • Research Publications
| January 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA’s rulemaking process for medical products involves extensive stakeholder participation and input from multiple branches of government and the public, but the process’s duration, complexity, and adversarial nature can impede the agency’s ability to achieve its public health objectives, with considerable variation in transparency across different stages. The authors recommend reforms focused on improving both transparency and efficiency in the rulemaking process to address delays in finalization timelines.
View Source

Ensuring Medical Device Effectiveness and Safety: A Cross-National Comparison of Approaches to Regulation

Kramer DB, Tan YT, Sato C, Kesselheim AS - Food and Drug Law Journal

  • Research Publications
| January 2014
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This cross-national legal and policy review identifies that major medical device regulatory markets in the US, EU, Japan, and China rely heavily on passive adverse event reporting but are increasingly adopting active surveillance mechanisms such as unique device identification. The authors recommend that US and EU regulators implement scheduled, compulsory re-examination of selected devices similar to practices in Japan and China to enhance post-market patient protection and public health outcomes.
View Source

New and Unproved Medical Devices

Kesselheim AS, Avorn J - BMJ

  • Commentary & Opinion
| December 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The rapid adoption of new medical devices by “innovator” and “early adopter” surgeons—as demonstrated by half of hip prosthesis brands in use having been on the market less than three years—poses public health risks because most devices are cleared through the 510(k) pathway without clinical effectiveness testing.
View Source

Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA

Wang B, Avorn J, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Research Publications
| December 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA denied approval in the first review cycle for 52% of new drugs and biologics evaluated by FDA advisory committees between 2007 and 2009, though 63% eventually received approval by 2013, with products initially flagged for safety concerns being far more likely to achieve eventual approval (62%) compared to those with efficacy concerns (8%).
View Source

Same Song, Different Audience: Pharmaceutical Promotion Targeting Non-Physician Health Care Providers

Yeh JS, Kesselheim AS - PLOS Medicine

  • Commentary & Opinion
| November 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Pharmaceutical marketing has expanded to target non-physician providers such as nurse practitioners and physician assistants, who now have significant prescribing authority. The authors argue that the same evidence showing promotional influence on physician prescribing likely applies to these providers.
View Source

The Role of Direct-To-Consumer Pharmaceutical Advertising in Patient Consumerism

Wang B, Kesselheim AS - AMA Journal of Ethics

  • Research Publications
| November 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Direct-to-consumer (DTC) pharmaceutical advertising in the US totaled more than $4 billion in 2012 and is increasingly delivered through digital channels like smartphones and the Internet. While these advertisements can inform patients about treatment options, the absence of firm regulatory guidelines governing DTC advertising may result in suboptimal treatment decisions and negative health and economic outcomes.
View Source

Physician Trainees’ Interactions with the Pharmaceutical Industry (Reply)

Austad KE, Avorn J, Franklin JM, Kesselheim AS - Journal of General Internal Medicine

  • Commentary & Opinion
| October 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this reply, the authors clarify that their finding should not diminish the importance of institutional policies on industry interactions. They emphasize that meaningful enforcement of such policies remains essential and that further research is needed to identify the most effective interventions.
View Source

Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs

Light DW, Lexchin J, Darrow JJ - Journal of Law, Medicine & Ethics

  • Research Publications
| Fall 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Institutional corruption in the pharmaceutical industry has enabled companies to hide, misrepresent, or ignore drug safety evidence, resulting in millions of adverse patient reactions despite limited therapeutic benefits. The authors argue that institutional corruption, rather than isolated misconduct, is the underlying cause of the epidemic of pharmaceutical harms and the gap between marketed safety claims and actual patient outcomes.
View Source

Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the US, 1980-2009

Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS - Journal of Law, Medicine & Ethics

  • Research Publications
| Fall 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The authors examine patterns of FDA approval and subsequent withdrawal of new antibiotics and other antiinfective drugs over three decades, documenting the decline in new antibiotic approvals alongside the growing threat of antimicrobial resistance. The analysis underscores that sustainable long-term antibiotic effectiveness requires complementary strategies of conservation (infection control and stewardship to reduce demand) and production of novel agents, with policy reforms needed to address the commercial dynamics that have led manufacturers to underinvest in antibiotic development.
View Source

Prescription-Drug Coupons—No Such Thing as a Free Lunch

Ross JS, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| September 2013
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors examine the growing use of manufacturer drug coupons and copayment assistance programs, arguing that while they reduce patients’ immediate out-of-pocket costs, they undermine formulary-based cost management by steering patients toward expensive brand-name drugs when cheaper therapeutic alternatives are available.
View Source

Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China

Kramer DB, Tan YT, Sato C, Kesselheim AS - PLOS Medicine

  • Research Publications
| September 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
A comparison of medical device postmarket surveillance strategies across 4 major markets—the US, EU, Japan, and China—reveals significant differences in adverse event reporting systems, registry-based monitoring, and postmarket study requirements. The analysis highlights how each system’s approach to ongoing safety and effectiveness monitoring reflects different regulatory philosophies and institutional capacities, offering lessons for ongoing policy reforms in all 4 jurisdictions.
View Source

Who Is Now Responsible for Discovering and Warning About Adverse Effects of Generic Drugs?

Kesselheim AS, Green MD, Avorn J - JAMA

  • Commentary & Opinion
| September 2013
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors examine three Supreme Court decisions that created a legal gap in which generic drug manufacturers cannot be held liable for inadequate warnings (because they must use the brand-name label) while brand-name manufacturers may not be liable for generic products they didn’t produce, leaving patients injured by generic drugs with limited legal recourse.
View Source

The Medical Device Excise Tax—Over Before It Begins? (Reply)

Kramer DB, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| September 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this exchange, industry representatives challeng the authors’ analysis of the ACA’s 2.3% medical device excise tax, claiming it has already caused job losses, reduced R&D spending, and will not generate the predicted revenue benefits. The authors reply that they remain skeptical of industry’s anecdotal claims, note that imaging utilization data from Massachusetts do not support the critics’ conclusions due to confounding factors.
View Source

Speaking the Same Language? International Variations in the Safety Information Accompanying Top-Selling Prescription Drugs

Kesselheim AS, Franklin JM, Avorn J, Duke JD - BMJ Quality & Safety

  • Research Publications
| September 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Across 20 top-selling prescription drugs, prescribing information approved by different regulatory agencies showed substantial variations in safety content, with Canada reporting 50% more adverse drug reactions than the US, while the UK and Australia reported 15% and 21% fewer, respectively. Black box warnings also differing significantly in presence and content across countries. The authors recommend improved international coordination in presenting safety data to enhance the effectiveness of prescribing information for patient safety and decision-making.
View Source

Pharmaceutical Efficacy: The Illusory Legal Standard

Darrow JJ - Washington and Lee Law Review

  • Research Publications
| September 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The author argues that despite lengthy and expensive drug development processes, the FDA’s efficacy standard under the Federal Food, Drug, and Cosmetic Act permits approval of drugs with minimal effectiveness, as it requires only “substantial evidence” of an effect without establishing any meaningful threshold for the magnitude of that efficacy. The author concludes that FDA approval should not be interpreted as assurance that approved medicines, particularly new and expensive drugs, possess efficacy meaningfully greater than no effiacy at all, with the responsibility for determining acceptable efficacy levels delegated to market forces.
View Source

Patterns and Predictors of Generic Narrow Therapeutic Index Drug Use Among Older Adults

Gagne JJ, Polinski JM, Kesselheim AS, Choudhry NK, Hutchins D, Matlin OS, Tong A, Shrank WH - Journal of the American Geriatrics Society

  • Research Publications
| September 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 36,832 Medicare beneficiaries initiating narrow therapeutic index (NTI) drugs in 2006–2007, 81.5% started on generics, with older age, higher comorbidity burden, prior generic drug use, and residing in areas with high generic utilization all independently associated with greater likelihood of generic initiation. These findings suggest that demographic, clinical, and geographic factors are important determinants of brand versus generic NTI drug selection and may represent targets for educational interventions to reduce disparities in prescribing patterns.
View Source

Defining “Innovativeness” in Drug Development: A Systematic Review

Kesselheim AS, Wang B, Avorn J - Clinical Pharmacology & Therapeutics

  • Research Publications
| September 2013
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This systematic review of 42 studies found that conclusions about whether pharmaceutical innovation is declining depend critically on the measurement method used: studies using simple drug approval counts were more likely to find favorable innovation trends, while studies using other measures of innovation were more likely to find unfavorable trends or reach no conclusion. The ongoing debate about pharmaceutical innovation trends reflects fundamental disagreements about how to define and measure innovativeness in drug development, necessitating clearer methodological consensus.
View Source

Gene Patenting—The Supreme Court Finally Speaks

Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM - New England Journal of Medicine

  • Commentary & Opinion
| August 2013
  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.
The authors discuss the Supreme Court’s unanimous ruling in Association for Molecular Pathology v. Myriad Genetics that naturally occurring human DNA segments are not patentable, while synthetically created complementary DNA (cDNA) remains patentable. They outline the decision’s implications for genetic testing, personalized medicine, and biomedical research.
View Source

Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey

Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS - Journal of General Internal Medicine

  • Research Publications
| August 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among medical students and residents surveyed, industry-sponsored gifts increased significantly across training levels, rising from 33.0% among first-year students to 56.8% among fourth-year students and 54% among residents. The perception that physicians receive valuable education through industry interactions also increased from 64.1% to 79.8%. Schools with higher NIH funding reported fewer industry gifts, but institutional conflict of interest policies showed no association with reduced gift-giving. Despite recent policy efforts to limit pharmaceutical industry access to trainees, stronger or more effectively enforced policies may be needed to meaningfully reduce these interactions.
View Source

Regulation of Drugs for Early Alzheimer’s Disease

Light DW, Darrow JJ - New England Journal of Medicine

  • Commentary & Opinion
| July 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
In this exchange, the authors argue that further loosening FDA approval standards for early-stage Alzheimer’s drugs risks encouraging development of ineffective medications. The FDA officials reply their proposed accelerated approval framework for disease-modifying therapies in very early Alzheimer’s is distinct from symptom-based approvals and includes appropriate safeguards.
View Source

Balancing Access and Innovation: India’s Supreme Court Rules on Imatinib

Rajkumar R, Kesselheim AS - JAMA

  • Commentary & Opinion
| July 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The authors discuss the Indian Supreme Court’s decision upholding India’s patent law provision (Section 3(d)) that denied a patent on a new form of imatinib, discussing how India’s approach to limiting secondary patents on incremental drug modifications balances innovation incentives with access to essential medicines.
View Source

Views from Academia, Industry, Regulatory Agencies, and the Legal System (2nd Ed)

Avorn J, Mo J, Reynolds RF, Dal Pan GJ, Arlett P, Kesselheim AS - Textbook of Pharmacoepidemiology, 2nd Edition

  • Commentary & Opinion
| July 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
This textbook chapter presents four complementary perspectives on the role of pharmacoepidemiology across the drug lifecycle, covering its use in academia, industry, and regulatory agencies. The final section examines the legal system’s intersection with pharmacoepidemiology.
View Source

FTC v. Actavis: The Supreme Court Issues A Reversal on Reverse Payments

Kesselheim AS, Shiu N - Health Affairs Forefront

  • Commentary & Opinion
| June 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
In a 5-3 decision, the Supreme Court ruled that “reverse payment” settlements are not automatically shielded from antitrust scrutiny by the existence of a patent, rejecting the lower court’s permissive “scope of the patent” test. The Court applied a “rule of reason” standard allowing the FTC to challenge such agreements based on factors like payment size and justification, a ruling expected to reduce anticompetitive settlements that the FTC estimated cost consumers up to $35 billion per decade in delayed generic competition.
View Source

Op-Ed: Healing the Overwhelmed Physician

Avorn J - New York Times

  • Commentary & Opinion
| June 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
Physicians are overwhelmed by a flood of clinical evidence that is sometimes distorted by pharmaceutical industry funding of clinical-practice guidelines. The author advocates for independent “curator-docent” approaches—rigorous, conflict-free evidence synthesis paired with outreach programs like academic detailing—to help doctors navigate the literature and make prescribing decisions based on the best available science rather than industry marketing.
View Source

Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market

Kesselheim AS - PLOS Medicine

  • Commentary & Opinion
| June 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
Talk bubble graphics representing commentary and opinion.
The author examines how brand-name pharmaceutical manufacturers use “life-cycle management” strategies—including patents on peripheral product aspects, authorized generics, and product reformulations—to extend market exclusivity and delay generic competition, contributing to rising drug costs without corresponding clinical benefit.
View Source

The Most Transformative Drugs of the Past 25 Years: A Survey of Physicians

Kesselheim AS, Avorn J - Nature Reviews Drug Discovery

  • Research Publications
| June 2013
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Approximately 180 expert physicians across 15 medical specialties used an iterative Delphi process to identify the most transformative drugs approved over the past 25 years, with effectiveness and superiority over existing alternatives emerging as the primary factors influencing their assessments. The authors argue that establishing consensus on what constitutes transformative drug innovation can better inform strategic and legislative efforts to catalyze pharmaceutical development.
View Source

Crowdsourcing Clinical Trials

Darrow JJ - Minnesota Law Review

  • Research Publications
| June 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The article identifies a fundamental ethical flaw in pharmaceutical regulation: newly FDA-approved drugs are effectively “tested” on an unknowing general public in the months and years after approval, due to the inherent inability of even the largest preapproval clinical trials to detect rare adverse events. The author proposes a “crowdsourcing” framework to improve post-approval drug surveillance, addressing the gap between the limited safety data available at the time of FDA approval and the full risk profile that only emerges through widespread clinical use.
View Source

Distributions of Industry Payments to Massachusetts Physicians

Kesselheim AS, Robertson CT, Siri K, Batra P, Franklin JM - New England Journal of Medicine

  • Research Publications
| May 2013
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Analysis of Massachusetts mandatory disclosure data between 2009 and 2011 revealed 32,227 payments totaling $76.7 million to 11,734 physicians, with 25% of all licensed Massachusetts physicians receiving at least 1 payment—led by specialists such as urologists (61%), gastroenterologists (57%), and cardiologists (46%), compared to just 19% of general internists. Compensation for bona fide services accounted for 88% of total expenditures ($67.3 million). Between 2010 and 2011, the number of physicians receiving payments decreased while the average payment increased, likely reflecting the impact of institutional gift bans at major academic medical centers and a state law prohibiting most meals, though the meal ban was subsequently repealed.
View Source

The Medical Device Excise Tax—Over Before It Begins?

Kramer DB, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| May 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors discuss the Affordable Care Act’s 2.3% medical device excise tax and the intense industry lobbying that led to an overwhelming Senate vote for repeal, questioning whether the industry’s claims about job losses and innovation impacts were supported by evidence.
View Source

Drug Company Gifts to Medical Students: The Hidden Curriculum

Kesselheim AS - BMJ

  • Commentary & Opinion
| February 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The author discusses a study showing that medical school policies restricting pharmaceutical industry gifts to students were associated with decreased prescribing of heavily promoted brand-name drugs years later, suggesting that the “hidden curriculum” of institutional norms around industry relationships has lasting effects on prescribing behavior.
View Source

Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence

Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK - JAMA Internal Medicine

  • Research Publications
| February 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Changes in the color appearance of antiepileptic drugs significantly increase the risk of medication nonpersistence, with color discordance associated with a 27% increased odds of nonpersistence overall and a 53% increased odds among patients with seizure disorder diagnoses. The findings suggest that current regulatory policy permitting wide variation in the appearance of bioequivalent drugs should be reconsidered to reduce medication interruptions and their associated clinical and financial consequences.
View Source

FDA Regulation of Off-Label Drug Promotion Under Attack

Kesselheim AS, Mello MM, Avorn J - JAMA

  • Commentary & Opinion
| February 2013
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The Second Circuit’s Caronia decision, which held that the government cannot prosecute pharmaceutical sales representatives for truthful off-label promotion, threatens the FDA’s ability to ensure that drugs are marketed based on adequate evidence and could lead to more unsafe off-label prescribing.
View Source

The Ethics of Intellectual Property Rights in an Era of Globalization

Shah AK, Warsh J, Kesselheim AS - Journal of Law, Medicine & Ethics

  • Research Publications
| Winter 2013
  • Innovation Incentives and Competition
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The TRIPS Agreement, which became a condition for WTO membership, required developing countries to adopt pharmaceutical patent protections comparable to developed nations—fundamentally merging the debate over intellectual property with globalization and threatening access to affordable medicines in low- and middle-income countries where patients bear over 70% of health care costs directly. The authors examine the ethical tensions inherent in applying a uniform global intellectual property framework to pharmaceutical products.
View Source

An Exploration of Compulsory Licensing as an Effective Policy Tool for Antiretroviral Drugs in India

Jain D, Darrow JJ - Health Matrix: The Journal of Law-Medicine

  • Research Publications
| January 2013
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Compulsory licensing, a TRIPS-permitted mechanism allowing generic production of patented pharmaceuticals, represents an underutilized policy tool that governments can deploy to balance patent protection with affordable drug access, particularly in developing countries like India facing high HIV disease burden. Drawing on successful precedents in Brazil, Thailand, Canada, and the US, the authors conclude that compulsory licensing is a feasible policy instrument for India to facilitate access to essential medicines within the current patent regime.
View Source

Drug Labels: A Flawed Source of Data for Studying Orphan Drug Approvals

Kesselheim AS, Avorn J - Clinical Pharmacology & Therapeutics

  • Commentary & Opinion
| December 2012
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors critique a study comparing orphan and non-orphan drug development programs, arguing that using drug labels rather than FDA-designated pivotal trials as data sources introduces methodological flaws because labels contain many non-pivotal studies that obscure meaningful differences in the evidence standards applied to orphan versus non-orphan drugs.
View Source

Risk, Responsibility, and Generic Drugs

Kesselheim AS, Avorn J, Greene JA - New England Journal of Medicine

  • Commentary & Opinion
| November 2012
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
he authors addresses issues of risk and responsibility in the generic drug market, examining how legal and regulatory frameworks assign liability for adverse effects between brand-name and generic drug manufacturers and the implications for patient safety.
View Source

Origins of Medical Innovation: The Case of Coronary Artery Stents

Xu S, Avorn J, Kesselheim AS - Circulation: Cardiovascular Quality and Outcomes

  • Research Publications
| November 2012
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
An analysis of 245 patents related to bare metal coronary stents filed between 1984 and 1994 revealed that the foundational innovations originated from individual physician-inventors within academic medical centers and their associated private companies, with the most-cited patents dominated by entities created by or dependent on these independent academics. Over time, large public companies came to dominate the field, suggesting that policies aimed at fostering transformative medical device innovation would be most effective if targeted at supporting individual inventors during the early stages of technology development.
View Source

User Fees and Beyond—The FDA Safety and Innovation Act of 2012

Kramer DB, Kesselheim AS - New England Journal of Medicine

  • Commentary & Opinion
| October 2012
  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors discuss the FDA Safety and Innovation Act, which reauthorized FDA user fees and introduced new expedited pathways including the breakthrough therapy designation, noting that while user fees have become essential to FDA operations, the legislation’s emphasis on streamlining approvals raises questions about the balance between speed and evidence requirements.
View Source

The Food and Drug Administration Has the Legal Basis to Restrict Promotion of Flawed Comparative Effectiveness Research

Kesselheim AS, Avorn J - Health Affairs

  • Research Publications
| October 2012
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
The FDA possesses legal authority to restrict pharmaceutical manufacturers’ promotional claims based on flawed observational research that fails to meet the agency’s “substantial evidence” standard. As comparative effectiveness research methods improves, the FDA should develop formal guidance clarifying which high-quality observational studies can satisfy the legal standard of “adequate and well-controlled investigations” for promotional purposes.
View Source

Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could Be Extended for Decades

Amin T, Kesselheim AS - Health Affairs

  • Research Publications
| October 2012
  • Innovation Incentives and Competition
  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
An examination of the patent landscape for the HIV antiretrovirals ritonavir (Norvir) and lopinavir/ritonavir (Kaletra) identified 108 patents—many on secondary features like alternate formulations and methods of administration with questionable inventiveness—that could collectively delay generic competition until at least 2028, 12 years beyond expiration of the base compound patents and 39 years after the first ritonavir patents were filed. The authors argue that increased patent transparency, stricter patentability standards, and expanded opportunities to challenge patents are needed to curb inappropriate market exclusivity extensions and facilitate earlier access to lower-cost generics.
View Source

Insights From a National Conference: “Conflicts of Interest in the Practice of Medicine”

Kesselheim AS, Orentlicher D - Journal of Law, Medicine & Ethics

  • Commentary & Opinion
| Fall 2012
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.
The authors introduce proceedings from a national conference examining conflicts of interest in medicine, framing how financial relationships between physicians, industry, and health systems create tensions between personal interests and patient care responsibilities.
View Source

Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence

Robertson CT, Rose SL, Kesselheim AS - Journal of Law, Medicine & Ethics

  • Research Publications
| Fall 2012
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
This review synthesizes the evidence on how financial relationships between health care professionals and pharmaceutical or medical device companies affect professional behaviors, including prescribing patterns, clinical decision-making, and research conduct. The authors examine the mechanisms through which industry payments, gifts, meals, and other transfers of value influence physician behavior, providing an evidence base for policies aimed at managing conflicts of interest in health care.
View Source

A Randomized Study of How Physicians Interpret Research Funding Disclosures

Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J - New England Journal of Medicine

  • Research Publications
| September 2012
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
In a randomized experiment with 269 board-certified internists, physicians appropriately distinguished among trials of varying methodologic rigor, but disclosure of industry funding independently led them to rate trials as less rigorous, feel less confident in the results, and be roughly half as willing to prescribe the study drug compared to NIH-funded trials. These effects persisted across all levels of actual methodologic quality. These findings suggest that industry sponsorship carries a reputational penalty that may influence how clinical research is translated into practice, regardless of a study’s true scientific merit.
View Source

Changes in Direct-To-Consumer Pharmaceutical Advertising Following Shifts From Prescription-Only to Over-The-Counter Status

Greene JA, Choudhry NK, Kesselheim AS, Brennan TA, Shrank WH - JAMA

  • Research Publications
| September 2012
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
An analysis of 133 advertisements for 4 drugs (loratadine, omeprazole, orlistat, cetirizine) that switched from prescription to OTC status found that after the OTC shift, advertisements more frequently described benefits while the proportion mentioning specific adverse effects or precautions declined, as regulatory oversight shifted from the FDA’s “fair balance” requirement to the FTC’s more permissive “reasonable consumer” standard. These findings suggest that the transition from prescription to OTC status may reduce the quality of risk information provided to consumers in drug advertising.
View Source

Conflict of Interest Reporting By Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures

Kesselheim AS, Wang B, Studdert DM, Avorn J - PLOS Medicine

  • Research Publications
| August 2012
  • Price, Value, and Access
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.
Among 39 physicians and scientists identified as having undisclosed financial relationships with pharmaceutical companies for promoting off-label drug uses, only 15% of their published articles contained adequate disclosure of these relationships, with commentaries showing significantly lower disclosure rates than original research articles. Thse findings indicate that current journal disclosure practices are inadequate, highlighting the need for greater author compliance and journal enforcement of reporting requirements.
View Source

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.